Article

pubs.acs.org/joc

†,§

†

‡

†
Dan Li,

Development and Application of α‑Heteroatom Ketones in
Asymmetric Michael Reaction with β-trans-Nitroalkenes
Dongxu Yang,
†
Key Laboratory of Preclinical Study for New Drugs of Gansu Province, Lanzhou University, Lanzhou 730000, People’s Republic of
China
‡
State Key Laboratory for Oxo Synthesis and Selective Oxidation Lanzhou Institute of Chemical Physics, Chinese Academy of
Sciences, Lanzhou 730000, People’s Republic of China
§Collaborative Innovation Center of Chemical Science and Engineering (Tianjin), Tianjin 300071, China

and Rui Wang*,†,§

Linqing Wang,

Depeng Zhao,

*S Supporting Information

ABSTRACT: The successful design and application of a new
type of N-phenyl-imidazole-modiﬁed α-heteroatom ketones in
reactions with β-trans-
asymmetric anti-selective Michael
nitroalkenes is reported. High yields and enantioselectivities
could be obtained, and the corresponding conjugate adducts
could be further transformed into related chiral esters and
cyclopropane derivatives with excellent enantioselectivities.

■ INTRODUCTION
Direct asymmetric α-function of carbonyl compounds with β-
trans-nitroalkenes has been studied in detail as a classic
transformation and fundamental approach in developing novel
chiral catalysts and aﬀording useful optical moleculars bearing
two typical functional groups. Over the past decade, tremendous
methods involving various type of carbonyl compounds have
been devoted to realizing the asymmetric C−C bond formation
process with β-trans-nitroalkenes.1 It
is well-known that
aldehydes,2 ketones,3 ketoesters,4 and types of cyclic carbonyl
compounds5 have been reported as powerful nucleophiles in the
direct asymmetric conjugate addition with nitroalkenes.
However, in comparison with the well-documented studies of
α-carbon type nucleophiles, the reaction with the utility of α-
heteroatom nucleophiles, especially for simple linear aldehydes6
and ketones,7,8 has not been studied as extensively (Scheme 1).
On the basis of our recent work on the application of N-
phenyl-imidazole-modiﬁed ketones in asymmetric Michael
reaction with β-nitroalkenes by demonstrating a newly
developed 3-bromothiophene-modiﬁed chiral diamine ligand,9

Scheme 1. Diﬀerent Types of Nucleophiles in Asymmetric
Michael Reactions with β-trans-Nitroalkenes

and considering our recent studies on N,O-bidentate eﬀects on
metal-mediated asymmetric reactions,10 here we report a
relatively general method of N-phenyl-imidazole-modiﬁed α-
heteroatom ketones in enantioselective conjugate reaction with
β-nitroalkenes.
■ RESULTS AND DISCUSSION
As illustrated in Scheme 2, the imidazole-modiﬁed α-heteroatom
ketones could be easily prepared by simple substitution reactions
of α-chloroketone 1a with diﬀerent phenols, acids, thiophenols,
and thiols.11
<para sub=“opt”>
Having built the synthetic method of types of imidazole-
modiﬁed α-heteroatom ketones, we next evaluated the conjugate
reaction of ketone 1b with β-trans-nitroalkenes 2a using the
diamine/Ni(OAc)2 catalysts prepared from chiral diamine
ligands and Ni(OAc)2 in a 1:1 ratio.12 As the results show in
Table 1, serials of chiral diamine derivatives (Scheme 3) were
screened to eﬀect
the desired conjugate reaction. A 3-
bromothiophene-modiﬁed chiral diamine ligand L7 was proven
to be better at introducing highly enantioselectivity as compared
to other diamine units (Table 1, entries 1−10). Solvent changing
from THF to DCM, iPrOH, and dioxane did not give more
potential results (Table 1, entries 11−13). Changing the
reaction’s concentration from 0.2 to 0.05 M would slightly
decrease the ee values (Table 1, entries 14 and 15). Further
screening process displayed that the reactions carried out under 0
°C could enhance the result and further selection process of
additives found the introduction of 4 Å MS into the reaction
would improve the ee value to 97% (Table 1, entries 16−21). To
our delight, the reaction could also proceed smoothly with 5.0
</para>

Received:
Published: April 8, 2015

January 7, 2015

© 2015 American Chemical Society

4336

DOI: 10.1021/acs.joc.5b00013
J. Org. Chem. 2015, 80, 4336−4348

The Journal of Organic Chemistry

Scheme 2. Design of Strategies of α-Heteroatom Ketones in
Enantioselective Conjugate Reaction with β-trans-
Nitroalkenes

<para sub=“opt”>
mol % catalyst without decreasing the ee value (Table 1, entry
22).
</para>
<para sub="scope">
After the optimized conditions were established as afore-
mentioned, the substrate generality of the N-phenylimidazole-
modiﬁed α-thioketones with an array of β-nitroalkenes was
examined. As illustrated in Table 2, a serials of aromatic
nitroalkenes were tested in the conjugate reaction, and the
corresponding adducts 3a−3j were obtained in good to excellent
yields and enantioselectivities (Table 2). For heterocyclic
substrates, such as 2-furyl- and 2-thienyl-derived nitroalkenes,
the conjugate products were obtained in decreased diaster-
eoselectivities while maintaining a high level of ee values,
respectively (Table 2, 3k,3l). Two representative aliphatic β-
nitroalkenes were also tried in the conjugate reaction; the desired
adducts could be obtained in relatively lower diastereoselectiv-
ities (Table 2, 3m,3n). The reaction scope with respect to
</para>

Table 1. Screening for the Optimized Conditionsa

Article
<para sub="scope">
diﬀerent types of α-thioketones then was also investigated (Table
2). As the results show in the table, ketones equipped with
diﬀerent benzylthio groups could also be applied to the catalytic
asymmetric conjugate reactions. The desired conjugate adducts
3o, 3p, and 3q were smoothly generated in moderate
diastereoselectivities and excellent enantioselectivities, respec-
tively. The use of an α-ethanethioketone also led to good results,
and the absolute stereochemistry of the corresponding product
3r was unambiguously determined to be (S,S) by X-ray
crystallographic analysis,13 bearing the same absolute conﬁg-
uration of our previous studies of carbon substituent N-
phenylimidazole-modiﬁed ketones in conjugate reactions with
β-nitroalkenes.9 Additionally, 2-hydroxyethanethiol was also an
alternative sulfur source for this catalytic system, aﬀording the
desired conjugate adduct 3s with acceptable results.
</para>
<para sub="scope">
Encouraged by the above results obtained from the α-
thioketones, we next focused our attention on the adaptability of
N-phenylimidazole-modiﬁed α-oxyketones in this asymmetric
conjugate reaction. To our delight, the conjugate reaction
proceeded smoothly for the α-oxyketones. As the results show in
Table 3, aromatic nitroalkenes bearing either electron-deﬁcient
or electron-rich substituents are equally applicable, and
generated the desired adducts in good to excellent diaster-
eoselectivities and enantioselectivities (Table 3, 4a−4m). To be
noted, aromatic nitroalkenes with ortho-substituents or hetero-
cyclic groups displayed relative lower diastereoselectivities. Also,
aliphatic β-nitroalkenes that were also tolerable in the conjugate
reaction resulted in moderate yields and good diastereoselectiv-
ities and enantioselectivities (Table 3, 4n,4o). Furthermore, the
use of diﬀerent α-oxyketones also led to good results, and the
desired products 4p−4s were obtained in good yields and ee
values. It is notable that an acetic-modiﬁed ketone could be
applied to the conjugated reaction and generated the
corresponding product 4t smoothly with good results, while
the ketone equipped with a benzoate group cannot perform the
transformation and no desired product 4u was detected by TLC
</para>
entry
1
2
3
4
5
6
7
8
9
10
11

ligand
L1
L2
L3
L4
L5
L6
L7
L8
L9
L10
L7

solvent
THF
THF
THF
THF
THF
THF
THF
THF
THF
THF
DCM

ee (%)b

75
84
82
78
72
82
87
76
72
74
40

entry
12
13
14c
15c
16d
17d,e
18d,f
19g
20d,h
21d,i
22d,i,j

ligand

L7
L7
L7
L7
L7
L7
L7
L7
L7
L7
L7

solvent
dioxane
iPrOH
THF
dioxane
THF
THF
THF
THF
THF
THF
THF

ee (%)

87
79
79
81
91
85
81
91
90
97
97

aGeneral conditions: 1b (0.10 mmol), 2a (0.15 mmol), ligand/Ni(OAc)2 (10 mol %) in THF (0.20 M) at rt, 18 h. bee values were determined by
HPLC analysis. cReaction carried out with 0.05 M. dReaction carried out in 0 °C. eReaction carried out with 0.40 M. f20 mol % TEA was introduced
into the reaction. gReaction carried out at −10 °C. hReaction carried out with 0.10 M. i100 mg of 4 Å MS was introduced into the reaction. jReaction
carried out with 5.0 mol % ligand/Ni(OAc)2.

4337

DOI: 10.1021/acs.joc.5b00013
J. Org. Chem. 2015, 80, 4336−4348

The Journal of Organic Chemistry

Scheme 3. Screening of Chiral Diamine Ligands

Article
<para sub="scope">
analysis and 1H NMR studies, and we have not found any side
reactions and the relative starting materials could be recovered.
</para>
<para sub="scope">
We next explored the application of the α-chloroketone 1a in
this reaction. We found the related conjugate adducts could be
formed smoothly and resulted in acceptable diastereoselectivities
and good to excellent enantioselectivities (Table 4). The major
diastereoisomer’s absolute conﬁguration was determined to be
(S,S) by X-ray crystallographic analysis.13
</para>
<para sub="scope">
Our further trial of α-azoketones failed. It was found that using
this type of N-phenylimidazole-modiﬁed ketones could not
furnish the desired conjugate adducts under the current
conditions.14 No other side reactions were observed, but only
the relative starting materials were recovered. Now we are trying
other catalytic systems to realize this type of transformation.
</para>
<para sub="scope">
Next, some further transformations of the conjugate products
have been carried out. As shown in Scheme 4, the conjugate
adduct 3a and 4a could be transformed into esters after the
cleavage of the N-phenylimidazole group with the corresponding
alcohols. It should be noted the the diastereoselectivities of the
product would be dramatically dropped in the presence of 1,8-
diazabicyclo[5.4.0]undec-7-ene. So it is obvious that the reverse
process of diastereoselectivity easily occurred when the
heteroatom was equipped in adducts. To our delight, the adduct
5a could be easily transformed into cyclopropane derivatives
after treating it with a simple base such as potassium carbonate,
and the relative stereochemistry of 8 and 9 was determined by
NOESY analysis15 (Scheme 5).
</para>

Finally, a possible mechanism for this Ni(II)-catalyzed
conjugate reaction is proposed in Scheme 6. After the enolization
process of the α-heteroatom ketone and the coordination results
determined by the chiral environment of the catalyst, the
conjugate reaction would occur between the activated ketone
and nitroalkenes. On the basis of the absolute stereochemistry of
the conjugate products, we speculated the in situ generated (Z)-
enolate should be more stable than (E)-enolate due to the
sterically hindered eﬀects between the imidazole group and the
heteroatoms.

■ CONCLUSION

In summary, we have disclosed a relatively general method for
asymmetric conjugate Michael reaction of α-heteroatom ketones
with β-trans-nitroalkenes. Synthesis of the related α-heteroatom

ketones is easily handled, and the successful utilization of these
types of ketones in the conjugate reaction is described by
employing a 3-bromothiophene-derived chiral diamine/Ni-
(OAc)2 catalysis. The conjugate reactions of α-thio-, α-oxy-,
and α-chloro-ketones with nitroalkenes have been realized, but
the α-azoketones failed to perform the reaction under current
conditions, and still need further investigation. Additionally, the
corresponding adducts could be further transformed into related
chiral esters and cyclopropane derivatives with excellent
enantioselectivity; these compounds could act as key precursors
of a serial of chiral amino acids.16
■ EXPERIMENTAL SECTION
<para sub=“exp”>
General Remarks. Unless stated otherwise, all reactions were
carried out in ﬂame-dried glassware. All solvents were puriﬁed and dried
according to standard methods prior to use. 1H and 13C NMR spectra
were recorded on a spectrometer (300 and 75 MHz, respectively) and
internally referenced to tetramethylsilane signal or residual protio
solvent signals. Data for 1H NMR are recorded as follows: chemical shift
(δ, ppm), multiplicity (s = singlet, d = doublet, t = triplet, m = multiplet,
q = quartet or unresolved, coupling constant (s) in Hz, integration).
Data for 13C NMR are reported in terms of chemical shift (δ, ppm). IR
spectra were recorded on a FT-IR spectrometer, and only major peaks
were reported in cm−1. High-resolution mass spectra (HRMS) were
obtained by the ESI ionization sources with a time-of-ﬂight mass
analyzer. The ee value determination was carried out using chiral HPLC
with a UV-detector.
</para>
<para sub=“exp”>
Synthesis Procedure of α-Heteroatom Ketones. 2-Chloro-1-(1-
phenyl-1H-imidazol-2-yl)ethanone (1a). To 100 mL of vacuum ﬂame-
dried RBF was added N-phenylimidazole (10.0 mmol, 1.0 equiv) under
an argon atmosphere. The solution was cooled to −78 °C, and n-
butyllithium in hexanes (2.5 M, 10.0 mmol, 1.0 equiv) was added to the
ﬂask. The reaction mixture then was allowed to warm to rt over a 30 min
period. The reaction was cooled to −78 °C for 20 min before tert-
butylchloroacetate (12.5 mmol, 1.25 equiv) was added as a single
portion. The reaction was stirred at −40 °C for 5.0 h. The reaction was
quenched with 3 mL of H2O and diluted with 50 mL of EtOAc and 50
mL of brine. The aqueous layer was separated and extracted with 2 × 30
mL of EtOAc. The organic layers were combined and dried with
Na2SO4. The drying agent was removed by ﬁltration, and the ﬁltrate was
concentrated in vacuo. The crude reaction mixture was puriﬁed with a
short SiO2 column to produce the desired product. 1H NMR (300 MHz,
CDCl3) δ 7.50−7.46 (m, 3H), 7.32−7.28 (m, 3H), 7.26 (s, 1H), 4.96 (s,
2H) ppm; 13C NMR (75 MHz, CDCl3) δ 181.5, 140.1, 137.5, 130.2,
129.1, 129.0, 127.8, 125.8, 46.8 ppm; HRMS (ESI): C11H9ClN2O [M +
Na]+ calcd, 243.0296; found, 243.0304.
</para>
4338

DOI: 10.1021/acs.joc.5b00013
J. Org. Chem. 2015, 80, 4336−4348

The Journal of Organic Chemistry
Table 2. Substrates Scope with Respect to α-Thioketonesa

Article

aGeneral conditions: 1 (0.10 mmol), 2 (0.15 mmol), ligand/Ni(OAc)2 (5 mol %) in THF (0.20 M) at 0 °C for 24 h. bIsolated yields of the major
diastereoisomers were included in parentheses. cDetermined by 1H NMR analysis of crude reaction mixtures and isolated major diastereoisomers;
the dr values of the isolated major diastereoisomers were included in parentheses. dee values were determined by HPLC analysis. eCombined yields
of diastereoisomers. fThe reaction was carried out under 10 mol % catalyst.
<para sub=“exp”>
Representative Procedure A for the Synthesis of N-Phenyl-
imidazole-Modiﬁed α-Heteroatom Ketones. To 10 mL of vacuum
ﬂame-dried RBF were added 1a (1.0 mmol, 1.0 equiv), K2CO3 (1.0
mmol, 1.0 equiv), and DMF (2.0 mL), the reaction mixtures was stirred
at rt, then the substituent reagent (phenthiols or thioalcohols) (1.5

mmol, 1.5 equiv) was added to the reaction mixture and stirred at this
temperature, until the reaction was complete (monitored by TLC). The
reaction was quenched by the addition of NH4Cl and extracted with EA,
dried over Na2SO4, and concentrated under reduced pressure. The
</para>
4339

DOI: 10.1021/acs.joc.5b00013
J. Org. Chem. 2015, 80, 4336−4348

The Journal of Organic Chemistry
Table 3. Substrates Scope of N-Phenylimidazole-Modiﬁed α-Oxyketonesa

Article

4340

DOI: 10.1021/acs.joc.5b00013
J. Org. Chem. 2015, 80, 4336−4348

The Journal of Organic Chemistry

Table 3. continued

Article

aGeneral conditions: 1 (0.10 mmol), 2 (0.15 mmol), ligand/Ni(OAc)2 (5 mol %) in THF (0.20 M) at 0 °C for 24 h. bIsolated yields the products.
cDetermined by 1H NMR analysis of crude reaction mixtures. dee values were determined by HPLC analysis.

Table 4. Substrates Scope with Respect to α-Chloroketone
1aa

Scheme 4. Transformation of the Conjugate Products to
Esters

Scheme 5. Transformation of the Conjugate Products to
Cyclopropane Derivatives

aGeneral conditions: 1a (0.10 mmol), 2 (0.15 mmol),
ligand/
Ni(OAc)2 (5 mol %) in THF (0.20 M) at 0 °C for 24 h. bCombined
isolated product was
yields of diastereoisomers.
summarized in parentheses. dThe reaction was carried out under 10
mol % catalyst.

cdr value of

Scheme 6. Proposed Mechanism of the Conjugate Reaction
<para sub=“exp”>
residue was puriﬁed by chromatography on silica gel using petroleum/
EtOAc as the eluent to aﬀord compound 1. General yield > 70%.
</para>
<para sub=“exp”>
Representative Procedure B for the Synthesis of N-Phenyl-
imidazole-Modiﬁed α-Heteroatom Ketones. To 10 mL of vacuum
ﬂame-dried RBF were added 1a (1.0 mmol, 1.0 equiv), K2CO3 (1.0
mmol, 1.0 equiv), and DMF (2.0 mL), the reaction mixtures was stirred
at rt, then the substituent reagent (phenols) (1.5 mmol, 1.5 equiv) was
added to the reaction mixtures and stirred at this temperature, until the
reaction was complete (monitored by TLC). The reaction was
quenched by the addition of NH4Cl and extracted with EA, dried over
Na2SO4, and concentrated under reduced pressure. The residue was
puriﬁed by chromatography on silica gel using petroleum/EtOAc as the
eluent to aﬀord compound 1. General yield > 80%.
</para>
<para sub=“exp”>
Representative Procedure C for the Synthesis of N-Phenyl-
imidazole-Modiﬁed α-Heteroatom Ketones. To 10 mL of vacuum
ﬂame-dried RBF were added 1a (1.0 mmol, 1.0 equiv), the substituent
reagent (acids) (1.5 mmol, 1.5 equiv), and acetone (1.5 mL), the
</para>
4341

DOI: 10.1021/acs.joc.5b00013
J. Org. Chem. 2015, 80, 4336−4348

The Journal of Organic Chemistry

Article
<para sub=“exp”>
reaction mixture was stirred at rt, then Et3N (2.5 mmol, 2.5 equiv) was
added to the reaction mixtures and stirred at this temperature, until the
reaction was complete (monitored by TLC). The reaction was
quenched by the addition of NH4Cl and extracted with EA, dried over
Na2SO4, and concentrated under reduced pressure. The residue was
puriﬁed by chromatography on silica gel using petroleum/EtOAc as the
eluent to aﬀord compound 1.
</para>

<para sub=“exp”>
1-(1-Phenyl-1H-imidazol-2-yl)-2-(phenylthio)ethanone (1b). Syn-
thesized according to representative procedure A. 1H NMR (300 MHz,
CDCl3) δ 7.40 (d, J = 5.8 Hz, 5H), 7.27 (d, J = 10.3 Hz, 3H), 7.21 (s,
4H), 4.46 (s, 2H) ppm; 13C NMR (75 MHz, CDCl3) δ 184.8, 142.0,
137.9, 135.3, 129.9, 129.6, 129.0, 128.9, 128.8, 127.4, 126.5, 125.7, 40.8
ppm; HRMS (ESI): C17H14N2OS [M + H]+ calcd, 295.0900; found,
295.0909.
</para>
<para sub=“exp”>
2-(Benzylthio)-1-(1-phenyl-1H-imidazol-2-yl)ethanone (1c). Syn-
thesized according to representative procedure A. 1H NMR (300 MHz,
CDCl3) δ 7.50−7.44 (m, 3H), 7.36−7.30 (m, 4H), 7.30−7.26 (m, 3H),
7.23 (d, J = 6.9 Hz, 1H), 7.20 (s, 1H), 3.81 (s, 2H), 3.76 (s, 2H) ppm;
13C NMR (75 MHz, CDCl3) δ 185.2, 142.1, 138.1, 137.6, 129.8, 129.3,
129.1, 128.9, 128.5, 127.4, 127.1, 125.7, 36.2, 36.1 ppm; HRMS (ESI):
C18H16N2OS [M + H]+ calcd, 309.1056; found, 309.1068.
</para>
<para sub=“exp”>
2-((2-Bromobenzyl)thio)-1-(1-phenyl-1H-imidazol-2-yl)ethanone
(1d). Synthesized according to representative procedure A. 1H NMR
(300 MHz, CDCl3) δ 7.56 (d, J = 7.9, 1.1 Hz, 1H), 7.51−7.45 (m, 3H),
7.42 (dd, J = 7.6, 1.6 Hz, 1H), 7.33 (m, J = 4.3, 3.4 Hz, 2H), 7.29 (d, J =
0.9 Hz, 1H), 7.26−7.19 (m, 2H), 7.10 (td, J = 7.7, 1.7 Hz, 1H), 3.88 (s,
2H), 3.86 (s, 2H) ppm; 13C NMR (75 MHz, CDCl3) δ 185.1, 142.1,
138.1, 137.0, 133.3, 131.2, 129.9, 129.1, 128.9, 128.8, 127.5, 127.3, 125.7,
124.7, 36.5, 36.3 ppm; HRMS (ESI): C18H16N2O2 [M + H]+ calcd,
293.1285; found, 293.1294.
</para>
<para sub=“exp”>
NMR (75 MHz, CDCl3) δ 184.4, 149.4, 147.4, 140.6, 137.5, 129.9,
128.94, 128.9, 127.3, 125.8, 121.8, 120.6, 113.5, 111.9, 70.6, 55.8 ppm;
HRMS (ESI): C18H16N2O3 [M + H]+ calcd, 309.1234; found, 309.1246.
2-(3-Chlorophenoxy)-1-(1-phenyl-1H-imidazol-2-yl)ethanone
(1k). Synthesized according to representative procedure B. 1H NMR
(300 MHz, CDCl3) δ = 7.50−7.42 (m, 3H), 7.31 (m, J = 4.3, 2.5 Hz,
4H), 7.20−7.12 (m, 1H), 6.93 (m, J = 4.3, 2.3 Hz, 2H), 6.83 (dd, J = 8.3,
1.7 Hz, 1H), 5.50 (s, 2H) ppm; 13C NMR (75 MHz, CDCl3) δ = 184.0,
158.7, 140.5, 137.4, 134.9, 130.26, 130.21, 129.1, 127.6, 125.9, 121.6,
115.1, 113.2, 69.9 ppm; HRMS (ESI): C17H13ClN2O2 [M + H]+ calcd,
313.0738; found, 313.0751.
</para>
<para sub=“exp”>
2-(Naphthalen-2-yloxy)-1-(1-phenyl-1H-imidazol-2-yl)ethanone
(1l). Synthesized according to representative procedure B. 1H NMR
(300 MHz, CDCl3) δ 7.81−7.64 (m, 3H), 7.51−7.37 (m, 4H), 7.37−
7.20 (m, 6H), 7.18 (s, 1H), 5.62 (s, 2H) ppm; 13C NMR (75 MHz,
CDCl3) δ 184.3, 155.9, 140.7, 134.3, 130.2, 129.6, 129.3, 129.1, 127.6,
127.5, 126.7, 126.4, 125.9, 123.9, 118.8, 107.1, 69.9 ppm; HRMS (ESI):
C21H16N2O2 [M + H]+ calcd, 329.1285; found, 329.1296.
</para>
<para sub=“exp”>
2-Oxo-2-(1-phenyl-1H-imidazol-2-yl)ethyl Acetate (1m). Synthe-
sized according to representative procedure C. 1H NMR (300 MHz,
CDCl3) δ 7.58−7.39 (m, 3H), 7.31 (m, J = 5.8 Hz, 3H), 7.24 (s, 1H),
5.49 (s, 2H), 2.14 (s, 3H) ppm; 13C NMR (75 MHz, CDCl3) δ 182.9,
170.4, 140.3, 137.5, 130.2, 129.1, 127.3, 125.9, 66.1, 20.5 ppm; HRMS
(ESI): C13H12N2O3 [M + Na]+ calcd, 267.0740; found, 267.0749.
</para>
<para sub=“exp”>
Isolated Nickel−Diamine Complex.12a A
mixture of diamine (L) (1.0 equiv) and nickel acetate tetrahydrate
(1.0 equiv) in ethanol was stirred for 2.0 h at room temperature. The
resulting solution was ﬁltered through a membrane ﬁlter. The ﬁltrate
was concentrated under reduced pressure. The residue was dissolved in
dichloromethane and concentrated under reduced pressure to give the
complex as a blue powder.
</para>

Preparation of
<para sub=“exp”>
General Procedure for the Asymmetric anti-Selective
Conjugate Reactions between Phenylimidazole-Modiﬁed Ke-
tones and Nitroalkenes. Ketones (0.10 mmol), Ni(OAc)2/L7 (5 mol
%, 0.005 mmol), nitroalkenes (0.15 mmol, 1.5 equiv), and 4 Å MS (100
mg) were weighed together in a ﬂame-dried round-bottom ﬂask. THF
(0.5 mL) was then added to the mixture, and the resulting solution was
stirred at 0 °C. After the starting material (ketones) was completely
consumed as monitored by TLC, the reaction mixture was ﬁltered
through a short pad of Celite (ethyl acetate), and concentrated in vacuo.
The crude mixture was puriﬁed by ﬂash column chromatography (EA/
PE = 1:4) to give adducts 3.
</para>
<para sub=“exp”>
(2S,3S)-4-Nitro-3-phenyl-1-(1-phenyl-1H-imidazol-2-yl)-2-
(phenylthio)butan-1-one (3a). White solid, mp 119−120 °C; 37.3 mg,
84% yield; 96.8% ee determined by HPLC on a Chiralpak OD-H
column (hexane/2-propanol = 60/40, ﬂow rate = 1.0 mL/min, tminor =
D = −70.2 (c = 1.08, CHCl3); 1H NMR
11.9 min, tmajor = 7.3 min); [α]rt
(300 MHz, CDCl3) δ = 7.54−7.48 (m, 2H), 7.42−7.35 (m, 2H), 7.35−
7.29 (m, 4H), 7.24−7.17 (m, 6H), 7.11 (d, J = 0.9 Hz, 1H), 6.92 (dd, J =
8.1, 1.5 Hz, 2H), 5.51−5.33 (m, 2H), 4.76 (dd, J = 12.7, 10.8 Hz, 1H),
4.15 (td, J = 11.1, 3.9 Hz, 1H) ppm; 13C NMR (75 MHz, CDCl3) δ =
183.7, 147.8, 141.9, 137.6, 137.0, 133.3, 132.3, 129.8, 129.3, 128.9, 128.8,
128.7, 128.4, 128.0, 127.5, 125.4, 79.1, 54.5, 45.0 ppm; IR (neat) 3356,
2925, 2400, 1554, 1403, 1262, 1104, 1042, 766, 696 cm−1; HRMS (ESI):
C25H21N3O3S [M + H]+ calcd, 444.1376; found, 444.1387.
</para>

<para sub=“exp”>
(2S,3S)-3-(4-Fluorophenyl)-4-nitro-1-(1-phenyl-1H-imidazol-2-
yl)-2-(phenylthio)butan-1-one (3b). Colorless oil; 36.0 mg, 78% yield;
98% ee determined by HPLC on a Chiralpak OD-H column (hexane/2-
propanol = 60/40, ﬂow rate = 1.0 mL/min, tminor = 10.0 min, tmajor = 6.7
D = −44.1 (c = 1.02, CHCl3); 1H NMR (300 MHz, CDCl3) δ
min); [α]rt
= 7.53−7.47 (m, 2H), 7.38 (dt, J = 5.5, 3.6 Hz, 3H), 7.35−7.29 (m, 3H),
7.24−7.14 (m, 4H), 7.02 (dd, J = 7.8, 1.6 Hz, 2H), 6.95−6.84 (m, 2H),
5.50−5.32 (m, 2H), 4.72 (dd, J = 12.7, 10.9 Hz, 1H), 4.12 (td, J = 11.3,
3.9 Hz, 1H) ppm; 13C NMR (75 MHz, CDCl3) δ = 183.4, 158.3 (d, J =
354.2 Hz), 141.9, 137.6, 133.4, 132.3 (d, J = 54.2 Hz), 130.1, 130.0,
129.9, 129.4, 129.0, 128.9, 128.8, 127.7, 125.4, 115.8 (d, J = 6.1 Hz),
80.0, 54.4, 44.1 ppm; IR (neat) 3356, 2924, 2368, 1883, 1684, 1554,
1403, 1219, 761, 693 cm−1; HRMS (ESI): C25H20FN3O3S [M + H]+
calcd, 462.1282; found, 462.1296.
</para>

4342

DOI: 10.1021/acs.joc.5b00013
J. Org. Chem. 2015, 80, 4336−4348
<para sub=“exp”>
2-((4-(tert-Butyl)benzyl)thio)-1-(1-phenyl-1H-imidazol-2-yl)-
ethanone (1e). Synthesized according to representative procedure A.
1H NMR (300 MHz, CDCl3) δ 7.47 (m, J = 6.6, 3.8 Hz, 3H), 7.31 (m, J =
4.8, 3.1 Hz, 4H), 7.27 (d, J = 6.1 Hz, 3H), 7.21 (s, 1H), 3.82 (s, 2H), 3.74
(s, 2H), 1.29 (s, 9H) ppm; 13C NMR (75 MHz, CDCl3) δ 187.3, 150.0,
142.2, 138.2, 134.5, 129.8, 129.1, 128.9, 128.8, 127.4, 125.7, 125.4, 36.2,
35.8, 34.5, 31.3 ppm; HRMS (ESI): C22H24N2OS [M + H]+ calcd,
365.1682; found, 365.1698.
</para>
<para sub=“exp”>
2-(Ethylthio)-1-(1-phenyl-1H-imidazol-2-yl)ethanone (1f). Synthe-
sized according to representative procedure A. 1H NMR (300 MHz,
CDCl3) δ 7.46 (m, J = 6.8, 3.8 Hz, 3H), 7.37−7.28 (m, 3H), 7.21 (s,
1H), 3.94 (s, 2H), 2.60 (q, J = 7.4 Hz, 2H), 1.25 (t, J = 7.4 Hz, 3H) ppm;
13C NMR (75 MHz, CDCl3) δ 185.2, 142.1, 138.1, 129.8, 129.0, 128.8,
127.4, 125.7, 37.0, 26.4, 14.3 ppm; HRMS (ESI): C13H14N2OS [M +
H]+ calcd, 247.0900; found, 247.0906.
</para>
<para sub=“exp”>
2-((2-Hydroxyethyl)thio)-1-(1-phenyl-1H-imidazol-2-yl)ethanone
(1g). Synthesized according to representative procedure A. 1H NMR
(300 MHz, CDCl3) δ 7.49−7.45 (m, 3H), 7.32−7.28 (m, 3H), 7.23 (d, J
= 0.7 Hz, 1H), 4.03 (s, 2H), 3.79 (t, J = 5.6 Hz, 2H), 2.80 (t, J = 5.6 Hz,
2H) ppm; 13C NMR (75 MHz, CDCl3) δ 185.7, 138.0, 129.9, 129.1,
129.0, 127.7, 125.7, 61.1, 37.2, 35.8 ppm; HRMS (ESI): C13H14N2O2S
[M + H]+ calcd, 263.0849; found, 263.0861.
</para>
<para sub=“exp”>
1-(1-Phenyl-1H-imidazol-2-yl)-2-(p-tolyloxy)ethanone (1h). Syn-
thesized according to representative procedure B. 1H NMR (300 MHz,
CDCl3) δ 7.55−7.37 (m, 3H), 7.31 (s,3H), 7.26 (s, 1H), 7.05 (d, J = 8.3
Hz, 2H), 6.84 (d, J = 8.5 Hz, 2H), 5.48 (s, 2H), 2.26 (s, 3H) ppm; 13C
NMR (75 MHz, CDCl3) δ 184.8, 155.9, 140.7, 130.6, 130.0, 129.9,
129.02, 129.0, 127.4, 125.9, 114.5, 70.0, 20.5 ppm; HRMS (ESI):
C18H16N2O2 [M + H]+ calcd, 293.1285; found, 293.1294.
</para>
<para sub=“exp”>
2-Phenoxy-1-(1-phenyl-1H-imidazol-2-yl)ethanone (1i). Synthe-
sized according to representative procedure B. 1H NMR (300 MHz,
CDCl3) δ 7.50−7.38 (m, 3H), 7.32 (d, J = 0.8 Hz, 2H), 7.27 (m, J = 10.7,
7.6, 4.5 Hz, 4H), 7.03−6.87 (m, 3H), 5.51 (s, 2H) ppm; 13C NMR (75
MHz, CDCl3) δ 184.6, 158.0, 140.6, 137.5, 130.1, 129.5, 129.04, 129.0,
127.4, 125.9, 121.3, 114.7, 69.8 ppm; HRMS (ESI): C17H14N2O2 [M +
H]+ calcd, 279.1128; found, 279.1137.
</para>
<para sub=“exp”>
2-(2-Methoxyphenoxy)-1-(1-phenyl-1H-imidazol-2-yl)ethanone
(1j). Synthesized according to representative procedure B. 1H NMR
(300 MHz, CDCl3) δ 7.52−7.37 (m, 3H), 7.28 (d, J = 14.8 Hz, 4H), 6.88
(ddd, J = 18.9, 9.8, 3.8 Hz, 4H), 5.59 (s, 2H), 3.85 (s, 3H) ppm; 13C
</para>
The Journal of Organic Chemistry

Article
<para sub=“exp”>
(2S,3S)-3-(4-Chlorophenyl)-4-nitro-1-(1-phenyl-1H-imidazol-2-
yl)-2-(phenylthio)butan-1-one (3c). Colorless oil; 38.7 mg, 81% yield;
97% ee determined by HPLC on a Chiralpak OD-H column (hexane/2-
propanol = 60/40, ﬂow rate = 1.0 mL/min, tminor = 11.4 min, tmajor = 7.2
D = −29.2 (c = 0.99, CHCl3); 1H NMR (300 MHz, CDCl3) δ
min); [α]rt
= 7.55−7.46 (m, 3H), 7.39 (d, J = 7.1 Hz, 3H), 7.36−7.30 (m, 3H), 7.24
(s, 1H), 7.18 (t, J = 5.6 Hz, 4H), 7.03 (d, J = 6.1 Hz, 2H), 5.41 (dd, J =
19.1, 7.7 Hz, 2H), 4.72 (dd, J = 12.7, 3 (s) 11.0 Hz, 1H), 4.10 (td, J =
11.3, 3.8 Hz, 1H) ppm; 13C NMR (75 MHz, CDCl3) δ = 183.2, 141.8,
137.5, 135.5, 133.9, 133.5, 131.8, 129.9, 129.7, 129.4, 129.0, 128.93,
128.9, 127.7, 125.4, 78.8, 54.2, 44.2 ppm; IR (neat) 3353, 2922, 2371,
1684, 1554, 1493, 1402, 757, 693, 531 cm−1; HRMS (ESI):
C25H20ClN3O3S [M + H]+ calcd, 478.0987; found, 478.1002.
</para>
<para sub=“exp”>
(2S,3S)-3-(4-Bromophenyl)-4-nitro-1-(1-phenyl-1H-imidazol-2-
yl)-2-(phenylthio)butan-1-one (3d). Colorless oil; 41.8 mg, 80% yield;
98% ee determined by HPLC on a Chiralpak OD-H column (hexane/2-
propanol = 60/40, ﬂow rate = 1.0 mL/min, tminor = 12.3 min, tmajor = 7.4
D = −14.6 (c = 0.89, CHCl3); 1H NMR (300 MHz, CDCl3) δ
min); [α]rt
= 7.50 (dd, J = 7.1, 2.3 Hz, 3H), 7.39 (d, J = 7.1 Hz, 3H), 7.33 (dd, J = 5.1,
3.4 Hz, 4H), 7.24 (s, 1H), 7.16 (s, 1H), 7.09 (d, J = 8.4 Hz, 2H), 7.03 (d,
J = 6.0 Hz, 2H), 5.49−5.31 (m, 2H), 4.77−4.65 (m, 1H), 4.16−4.03 (m,
1H) ppm; 13C NMR (75 MHz, CDCl3) δ = 183.2, 141.8, 137.5, 136.1,
133.5, 133.4, 131.9, 131.8, 130.0, 129.9, 129.4, 129.0, 128.9, 127.7, 125.4,
122.1, 78.8, 54.2, 44.3 ppm; IR (neat) 3351, 2925, 2370, 1554, 1403,
1217, 1112, 1043, 766, 692 cm−1; HRMS (ESI): C25H20BrN3O3S [M +
H]+ calcd, 522.0482; found, 522.0501.
</para>
<para sub=“exp”>
(2S,3S)-4-Nitro-1-(1-phenyl-1H-imidazol-2-yl)-2-(phenylthio)-3-
(p-tolyl)butan-1-one (3e). Colorless oil; 23.8 mg, 52% yield; 93% ee
determined by HPLC on a Chiralpak IA-H column (hexane/2-propanol
= 80/20, ﬂow rate = 1.0 mL/min, tminor = 11.4 min, tmajor = 52.6 min);
D = −101.6 (c = 1.04, CHCl3); 1H NMR (300 MHz, CDCl3) δ =
[α]rt
7.51 (m, J = 6.5, 2.8 Hz, 2H), 7.42−7.27 (m, 6H), 7.23 (s, 1H), 7.14−
7.05 (m, 3H), 7.00 (d, J = 8.0 Hz, 2H), 6.92 (d, J = 7.0 Hz, 2H), 5.54−
5.19 (m, 2H), 4.81−4.62 (t, 1H), 4.12 (m, J = 11.2, 3.8 Hz, 1H), 2.23 (s,
3H) ppm; 13C NMR (75 MHz, CDCl3) δ = 183.7, 141.9, 137.7, 137.6,
133.8, 133.3, 132.4, 129.8, 129.5, 129.3, 128.9, 128.8, 128.7, 128.2, 127.4,
125.4, 79.2, 54.7, 44.6, 21.1 ppm; IR (neat) 3353, 2924, 2372, 1685,
1554, 1402, 1217, 1024, 758, 693 cm−1; HRMS (ESI): C26H23N3O3S [M
+ H]+ calcd, 458.1533; found, 458.1554.
</para>
<para sub=“exp”>
(2S,3S)-3-(3-Chlorophenyl)-4-nitro-1-(1-phenyl-1H-imidazol-2-
yl)-2-(phenylthio)butan-1-one (3f). Colorless oil; 23.9 mg, 50% yield;
95% ee determined by HPLC on a Chiralpak IA-H column (hexane/2-
propanol = 60/40, ﬂow rate = 1.0 mL/min, tminor = 7.1 min, tmajor = 29.3
D = −42.4 (c = 0.99, CHCl3); 1H NMR (300 MHz, CDCl3) δ
min); [α]rt
= 7.50 (dd, J = 6.4, 2.9 Hz, 2H), 7.68−7.41 (m, 4H), 7.43−7.35 (m, 3H),
7.34−7.29 (m, 3H), 7.41−7.04 (m, 14H), 7.28−7.23 (m, 2H), 7.18−
7.10 (m, 4H), 7.04−6.92 (m, 2H), 7.05−6.96 (m, 2H), 5.52−5.32 (m,
2H), 5.50−5.34 (m, 2H), 4.74 (dd, J = 12.9, 10.9 Hz, 1H), 4.74 (dd, J =
12.9, 10.9 Hz, 1H), 4.10 (td, J = 11.2, 3.8 Hz, 1H), 4.10 (td, J = 11.2, 3.8
Hz, 1H) ppm; 13C NMR (75 MHz, CDCl3) δ = 183.3, 141.8, 139.1,
137.5, 134.6, 133.4, 131.9, 130.1, 130.0, 129.4, 129.0, 128.9, 128.88,
128.85, 128.3, 127.8, 126.2, 125.4, 78.6, 54.2, 44.6 ppm; IR (neat) 3349,
2924, 2372, 1684, 1554, 1402, 1217, 1085, 758, 693 cm−1; HRMS (ESI):
C25H20ClN3O3S [M + H]+ calcd, 478.0987; found, 478.1004.
</para>
<para sub=“exp”>
(2S,3S)-4-Nitro-1-(1-phenyl-1H-imidazol-2-yl)-2-(phenylthio)-3-
(m-tolyl)butan-1-one (3g). Colorless oil; 30.1 mg, 66% yield; 95% ee
determined by HPLC on a Chiralpak OD-H column (hexane/2-
propanol = 60/40, ﬂow rate = 1.0 mL/min, tminor = 8.8 min, tmajor = 6.2
D = −58.9 (c = 1.04, CHCl3); 1H NMR (300 MHz, CDCl3) δ
min); [α]rt
= 7.52 (dd, J = 6.6, 3.0 Hz, 2H), 7.42−7.35 (m, 2H), 7.32 (dd, J = 6.1, 3.4
Hz, 4H), 7.23 (s, 1H), 7.13−7.05 (m, 2H), 6.99 (t, J = 8.5 Hz, 3H), 6.91
(d, J = 6.8 Hz, 2H), 5.49−5.34 (m, 2H), 4.75 (dd, J = 12.6, 10.8 Hz, 1H),
4.10 (td, J = 11.2, 3.8 Hz, 1H), 2.22 (s, 3H) ppm; 13C NMR (75 MHz,
CDCl3) δ = 183.8, 142.0, 138.4, 137.6, 136.8, 133.3, 132.3, 129.8, 129.4,
129.3, 128.9, 128.8, 128.7, 128.67, 128.64, 127.4, 125.4, 125.1, 79.1, 54.5,
45.0, 21.3 ppm; IR (neat) 3354, 3021, 2924, 2402, 1685, 1554, 1403,
1217, 758, 694 cm−1; HRMS (ESI): C26H23N3O3S [M + H]+ calcd,
458.1533; found, 458.1550.
</para>

<para sub=“exp”>
(2S,3S)-3-(2-Fluorophenyl)-4-nitro-1-(1-phenyl-1H-imidazol-2-
yl)-2-(phenylthio)butan-1-one (3h). Colorless oil; 28.6 mg, 61% yield;

94%/88% ee determined by HPLC on a Chiralpak IA-H column
(hexane/2-propanol = 80/20, ﬂow rate = 1.0 mL/min, tminor = 7.0 min,
D = −31.3 (c = 1.05, CHCl3); 1H NMR (300 MHz,
tmajor = 7.9 min); [α]rt
CDCl3) δ = 7.50 (m, J = 6.3, 3.0 Hz, 2H), 7.37 (t, J = 6.7 Hz, 2H), 7.34−
7.28 (m, 3H), 7.24 (d, J = 11.5, 5.3 Hz, 3H), 7.20−7.10 (m, 3H), 6.97
(m, J = 15.3, 7.0 Hz, 3H), 5.68 (t, J = 9.8 Hz, 1H), 5.35 (dd, J = 13.0, 4.0
Hz, 1H), 4.98 (dd, J = 12.9, 10.1 Hz, 1H), 4.30 (td, J = 10.5, 4.9 Hz, 1H).
13C NMR (75 MHz, CDCl3) δ = 183.5, 161.0 (d, J = 245.8 Hz), 141.7,
137.6, 133.0, 131.5 (d, J = 4.2 Hz), 130.0, 129.9 (d, J = 8.6 Hz), 129.4,
129.2, 129.0, 128.9, 128.8, 128.7, 127.6, 125.4, 124.4 (d, J = 3.3 Hz),
123.8 (d, J = 12.8 Hz), 116.1(d, J = 21.8 Hz), 53.3, 41.0. IR (neat) 3351,
2925, 2370, 1683, 1554, 1403, 1217, 1106, 760, 692 cm−1; HRMS (ESI):
C25H20FN3O3S [M + H]+ calcd, 462.1282; found, 462.1303.
</para>
<para sub=“exp”>
(2S,3S)-3-(4-Methoxyphenyl)-4-nitro-1-(1-phenyl-1H-imidazol-2-
yl)-2-(phenylthio)butan-1-one (3i). Colorless oil; 42.2 mg, 90% yield
(2.8:1 dr); 94% ee determined by HPLC on a Chiralpak IA-H column
(hexane/2-propanol = 60/40, ﬂow rate =1.0 mL/min, tminor = 8.2 min,
D = −37.9 (c = 1.03, CHCl3); 1H NMR (300
tmajor = 37.2 min); [α]rt
MHz, CDCl3) δ = 7.56−7.45 (m, 2H), 7.39−7.21 (m, 7H), 7.16−7.06
(m, 3H), 7.02−6.91 (m, 2H), 6.82−6.67 (d, 2H), 5.53 (dd, J = 9.5 Hz,
2H), 4.91−4.63 (dd, 1H), 4.18−3.93 (m, 1H), 3.72 (s, J = 18.0 Hz, 3H).
13C NMR (75 MHz, CDCl3) δ = 185.5, 183.7, 159.2, 141.9, 137.8, 137.6,
133.9, 133.3, 132.3, 130.1, 129.8, 129.6, 129.4, 129.3, 129.2, 129.1, 129.0,
128.8, 128.72, 128.7, 128.6, 128.3, 127.9, 127.5, 125.6, 125.4, 114.2,
114.1, 79.2, 55.7, 55.2, 55.1, 54.6, 44.6, 44.3. IR (neat) 3369, 2924, 2853,
2369, 1797, 1553, 1254, 1120, 1033, 762 cm−1; HRMS (ESI):
C26H23N3O4S [M + H]+ calcd, 474.1482; found, 474.1496.
</para>
<para sub=“exp”>
(2S,3S)-3-(3,5-Dimethoxyphenyl)-4-nitro-1-(1-phenyl-1H-imida-
zol-2-yl)-2-(phenylthio)butan-1-one (3j). Colorless oil; 42.3 mg, 84%
yield (2.9:1 dr); 94% ee determined by HPLC on a Chiralpak IA-H
column (hexane/2-propanol = 60/40, ﬂow rate = 1.0 mL/min, tminor =
D = −72.0 (c = 1.00, CHCl3);1H NMR
9.8 min, tmajor = 32.8 min); [α]rt
(300 MHz, CDCl3) δ = 7.57−7.45 (m, 2H), 7.41−7.19 (m, 7H), 7.13 (s,
J = 0.5 Hz, 1H), 6.97 (dd, J = 7.9, 2 Hz, 1H), 6.40−6.21 (m, 3H), 5.43
(dd, J = 17.5, 16.5, 6.6 Hz, 2H), 4.91−4.66 (dd, 1H), 4.13−3.93 (m,
1H), 3.66 (d, J = 11.1 Hz, 6H). 13C NMR (75 MHz, CDCl3) δ = 185.3,
183.6, 160.8, 142.0, 139.3, 138.7, 137.6, 133.8, 133.4, 132.1, 130.1, 129.8,
129.3, 129.2, 129.1, 128.9, 128.8, 128.7, 128.5, 128.0, 127.5, 125.6, 125.4,
106.7, 106.1, 100.4, 99.9, 79.1, 77.7, 55.4, 55.3, 54.0, 45.4, 45.6, 45.2. IR
(neat) 3366, 2925, 2854, 2370, 1738, 1596, 1461, 1155, 1027, 761 cm−1;
HRMS (ESI): C27H25N3O5S [M + H]+ calcd, 504.1588;
found,
504.1603.
</para>
<para sub=“exp”>
(2S,3R)-3-(Furan-2-yl)-4-nitro-1-(1-phenyl-1H-imidazol-2-yl)-2-
(phenylthio)butan-1-one (3k). Colorless oil; 40.9 mg, 94% yield (1.5:1
dr); 92%/92% ee determined by HPLC on a Chiralpak IA-H column
(hexane/2-propanol = 80/20, ﬂow rate = 1.0 mL/min, tminor = 7.2/8.0
D = −10.8 (c = 1.02, CHCl3); 1H NMR
min, tmajor = 9.7/16.6 min); [α]rt
(300 MHz, CDCl3) δ = 7.44 (m, J = 12.7, 6.2, 2.9 Hz, 5H), 7.34−7.24
(m, 6H), 7.22−7.12 (m, 2H), 6.32−6.04 (m, 2H), 5.51 (d, J = 10.9 Hz,
1H), 5.35−4.76 (m, 2H), 4.30 (td, J = 10.4, 3.7 Hz, 1H) ppm; 13C NMR
(75 MHz, CDCl3) δ = 184.8, 183.6, 149.9, 142.5, 141.9, 141.6, 137.7,
133.9, 133.2, 131.9, 130.2, 130.0, 129.3, 129.2, 129.1, 129.0, 128.9, 128.8,
128.7, 128.0, 127.7, 125.6, 110.4, 109.2, 76.2, 75.8, 53.9, 52.9, 39.3, 38.6
ppm; IR (neat) 3298, 2924, 2372, 1683, 1555, 1402, 1148, 1016, 758,
693 cm−1; HRMS (ESI): C23H19N3O4S [M + H]+ calcd, 434.1169;
found, 434.1186.
</para>
<para sub=“exp”>
(2S,3S)-4-Nitro-1-(1-phenyl-1H-imidazol-2-yl)-2-(phenylthio)-3-
(thiophen-2-yl)butan-1-one (3l). Colorless oil; 35.5 mg, 79% yield
(2.0:1 dr); 95%/95% ee determined by HPLC on a Chiralpak OD-H
column (hexane/2-propanol = 60/40, ﬂow rate = 1.0 mL/min, tminor =
D = −54.9 (c = 1.02, CHCl3); 1H NMR
13.2 min, tmajor = 8.3 min); [α]rt
(300 MHz, CDCl3) δ = 7.50−7.47 (m, 2H), 7.40 (s, 2H), 7.34−7.28 (m,
4H), 7.26 (s, 2H), 7.16 (s, 1H), 7.04 (m, J = 7.6, 1.6 Hz, 2H), 6.89 (t, J =
2.8 Hz, 2H), 5.44 (d, J = 11.4 Hz, 1H), 4.93 (d, J = 6.5 Hz, 1H), 4.76 (dd,
J = 12.8, 10.3 Hz, 1H), 4.49 (td, J = 10.7, 3.7 Hz, 1H) ppm; 13C NMR
(75 MHz, CDCl3) δ = 184.0, 182.2, 140.7, 138.4, 136.6, 132.8, 132.3,
130.9, 129.2, 128.9, 128.3, 128.13, 128.1, 128.0, 127.9, 127.8, 127.7,
127.0, 126.6, 126.1, 125.9, 125.8, 124.5, 124.4, 124.3, 78.3, 77.3, 55.5,
54.0, 40.0, 39.2, 0.0 ppm; IR (neat) 3351, 2924, 2854, 1684, 1555, 1402,
</para>
4343

DOI: 10.1021/acs.joc.5b00013
J. Org. Chem. 2015, 80, 4336−4348

The Journal of Organic Chemistry
1306, 1217, 759, 694 cm−1; HRMS (ESI): C23H19N3O3S2 [M + H]+
calcd, 450.0941; found, 450.0959.
<para sub=“exp”>
(2S,3S)-3-(Nitromethyl)-1-(1-phenyl-1H-imidazol-2-yl)-2-
(phenylthio)nonan-1-one (3m). Colorless oil; 38.2 mg, 85% yield
(1.6:1 dr); 94%/92% ee determined by HPLC on a Chiralpak IA-H
column (hexane/2-propanol = 60/40, ﬂow rate = 1.0 mL/min, tminor =
4.3/4.6 min, tmajor = 5.2/8.1 min); [α]rt
D =19.5(c = 0.97, CHCl3); 1H
NMR (300 MHz, CDCl3) δ = 7.57−7.52 (m, 1H), 7.50−7.42 (m, 4H),
7.34−7.24 (m, 6H), 7.24 (s, 1H), 5.44 (d, J = 37.3, 7.7 Hz, 1H), 4.93 (dd,
J = 16.3, 13.1, 3.7 Hz, 1H), 4.61 (dd, J = 27.1, 13.1, 8.0 Hz, 1H), 3.04−
2.62 (m, 1H), 1.54−1.40 (m, 2H), 1.38−1.27 (m, 2H), 1.24−1.10 (m,
6H), 0.84 (m, J = 11.6, 7.0 Hz, 3H) ppm; 13C NMR (75 MHz, CDCl3) δ
= 185.3, 142.1, 137.9, 133.4, 132.9, 130.0, 129.3−128.7 (m), 128.5,
128.2, 127.9, 125.6, 76.5, 54.2, 53.9, 39.4, 38.5, 31.4, 30.1, 29.0, 26.1,
22.5, 14.0 ppm; IR (neat) 3348, 2927, 2858, 2374, 1681, 1551, 1445,
1402, 757, 693 cm−1; HRMS (ESI): C25H29N3O3S [M + H]+ calcd,
452.2002; found, 452.2020.
</para>
<para sub=“exp”>
(2S,3S)-4-Methyl-3-(nitromethyl)-1-(1-phenyl-1H-imidazol-2-yl)-
2-(phenylthio)pentan-1-one (3n). Colorless oil; 35.8 mg, 87% yield;
94% ee determined by HPLC on a Chiralpak OD-H column (hexane/2-
propanol = 60/40, ﬂow rate = 1.0 mL/min, tminor = 5.5 min, tmajor = 5.0
D = 59.1 (c = 1.07, CHCl3); 1H NMR (300 MHz, CDCl3) δ =
min); [α]rt
7.61 (dd, J = 6.4, 2.9 Hz, 1H), 7.46 (m, J = 8.4, 5.7 Hz, 4H), 7.37−7.29
(m, 2H), 7.29−7.21 (m, 5H), 5.33 (d, J = 9.8 Hz, 1H), 4.95 (dd, J = 14.1,
3.9 Hz, 1H), 4.54 (dd, J = 14.1, 7.1 Hz, 1H), 3.09 (m, J = 10.5, 3.5 Hz,
1H), 1.99−1.75 (m, 1H), 0.98−0.79 (m, 6H) ppm; 13C NMR (75 MHz,
CDCl3) δ = 185.2, 183.7, 141.0, 136.8, 132.5, 132.1, 131.8, 129.0,
128.5−127.8 (m), 127.6, 127.1, 126.6, 124.5, 76.4, 76.0, 75.6, 74.9, 73.5,
52.6, 45.1, 42.1, 28.4, 19.4, 18.9, 18.6, 16.6 ppm; IR (neat) 3343, 2963,
2399, 1682, 1553, 1401, 1261, 1024, 758, 693 cm−1; HRMS (ESI):
C22H23N3O3S [M + H]+ calcd, 410.1533; found, 410.1540.
</para>
<para sub=“exp”>
(2S,3S)-2-(Benzylthio)-4-nitro-3-phenyl-1-(1-phenyl-1H-imidazol-
2-yl)butan-1-one (3o). Colorless oil; 31.7 mg, 69% yield; 95% ee
determined by HPLC on a Chiralpak OD-H column (hexane/2-
propanol = 60/40, ﬂow rate = 1.0 mL/min, tminor = 10.2 min, tmajor = 9.1
D = −210.3 (c = 0.98, CHCl3); 1H NMR (300 MHz, CDCl3)
min); [α]rt
δ = 7.47 (d, J = 7.0 Hz, 2H), 7.37 (m, J = 11.0, 8.8, 4.5 Hz, 6H), 7.27 (s,
1H), 7.21−7.10 (m, 6H), 6.98 (dd, J = 7.7, 1.6 Hz, 2H), 5.03 (d, J = 11.4
Hz, 1H), 4.92−4.84 (m, 1H), 4.12−3.95 (m, 2H), 3.87 (q, J = 13.1 Hz,
2H) ppm; 13C NMR (75 MHz, CDCl3) δ = 183.4, 142.4, 137.7, 137.6,
137.4, 129.8, 129.44, 129.41, 129.0, 128.9, 128.88, 128.8, 128.2, 127.9,
127.5, 125.2, 78.8, 49.5, 43.0, 35.9 ppm; IR (neat) 3349, 2924, 2373,
1681, 1552, 1382, 1261, 1099, 760, 698 cm−1; HRMS (ESI):
C26H23N3O3S [M + H]+ calcd, 458.1533; found, 458.1538.
</para>
<para sub=“exp”>
(2S,3S)-2-((2-Bromobenzyl)thio)-4-nitro-3-phenyl-1-(1-phenyl-
1H-imidazol-2-yl)butan-1-one (3p). Colorless oil; 41.5 mg, 77% yield;
91% ee determined by HPLC on a Chiralpak OD-H column (hexane/2-
propanol = 60/40, ﬂow rate =1.0 mL/min, tminor = 27.2 min, tmajor = 24.5
D = −167.0 (c = 1.03, CHCl3); 1H NMR (300 MHz, CDCl3)
min); [α]rt
δ = 7.59 (t, J = 9.2 Hz, 2H), 7.42−7.31 (m, 4H), 7.26 (s, 1H), 7.23−7.11
(m, 7H), 7.00 (dd, J = 7.6, 1.5 Hz, 2H), 5.16−4.95 (m, 2H), 4.29−4.15
(m, 1H), 4.07 (dd, J = 11.5, 3.6 Hz, 1H), 4.01 (s, 2H) ppm; 13C NMR
(75 MHz, CDCl3) δ = 183.3, 142.4, 137.7, 137.3, 136.4, 133.6, 131.5,
129.8, 129.6, 129.0, 128.8, 128.2, 127.9, 127.6, 127.5, 125.2, 124.9, 78.8,
49.5, 43.1, 36.4 ppm; IR (neat) 3346, 2924, 2395, 1683, 1552, 1493,
1379, 1027, 758, 697 cm−1; HRMS (ESI): C26H22BrN3O3S [M + H]+
calcd, 536.0638; found, 536.0643.
</para>
<para sub=“exp”>
(2S,3S)-2-((4-(tert-Butyl)benzyl)thio)-4-nitro-3-phenyl-1-(1-phe-
nyl-1H-imidazol-2-yl)butan-1-one (3q). Colorless oil; 36.1 mg, 70%
yield; 95% ee determined by HPLC on a Chiralpak OD-H column
(hexane/2-propanol = 60/40, ﬂow rate = 1.0 mL/min, tminor = 8.0 min,
D = −169.2 (c = 0.99, CHCl3); 1H NMR (300
tmajor = 6.5 min); [α]rt
MHz, CDCl3) δ = 7.49−7.32 (m, 8H), 7.30−7.23 (m, 2H), 7.15 (m, J =
18.3, 6.6 Hz, 6H), 6.99 (dd, J = 7.7, 1.7 Hz, 2H), 5.09−4.97 (m, 1H),
4.91−4.75 (m, 1H), 4.01−3.90 (m, 2H), 3.80 (dd, J = 26.8, 13.8 Hz,
2H), 1.33 (s, 9H) ppm; 13C NMR (75 MHz, CDCl3) δ = 183.3, 151.1,
142.4, 137.8, 137.7, 134.3, 129.8, 129.2, 129.0, 128.8, 128.2, 127.8, 127.4,
125.8, 125.2, 78.7, 49.6, 42.9, 35.7, 34.7, 31.4 ppm; IR (neat) 3347, 2964,
2370, 1684, 1554, 1494, 1404, 1217, 758, 697 cm−1; HRMS (ESI):
C30H31N3O3S [M + H]+ calcd, 514.2159; found, 514.2166.
</para>
Article
<para sub=“exp”>
(2S,3S)-2-(Ethylthio)-4-nitro-3-phenyl-1-(1-phenyl-1H-imidazol-
2-yl)butan-1-one (3r). White solid, mp 163−165 °C; 31.7 mg, 80%
yield; 97% ee determined by HPLC on a Chiralpak OD-H column
(hexane/2-propanol = 60/40, ﬂow rate = 1.0 mL/min, t = 6.3 min);
D = −138.0 (c = 0.50, CHCl3); 1H NMR (300 MHz, CDCl3) δ =
[α]rt
7.41−7.31 (m, 3H), 7.28−7.23 (m, 4H), 7.23−7.18 (m, 2H), 7.11 (d, J =
0.7 Hz, 1H), 6.94 (dd, J = 7.9, 1.5 Hz, 2H), 5.32 (dd, J = 12.8, 4.0 Hz,
1H), 5.12 (d, J = 11.8 Hz, 1H), 4.79 (dd, J = 12.7, 10.5 Hz, 1H), 4.08
(ddd, J = 11.6, 10.6, 4.0 Hz, 1H), 2.83−2.53 (m, 2H), 1.25 (t, J = 7.5 Hz,
4H) ppm; 13C NMR (75 MHz, CDCl3) δ = 183.0, 142.2, 137.7, 137.4,
129.7, 129.0, 128.8, 128.7, 128.2, 128.0, 127.4, 125.2, 79.3, 49.6, 43.0,
24.4, 14.1 ppm; IR (neat) 3342, 2923, 2375, 1594, 1545, 1382, 1112,
771, 700, 627 cm−1; HRMS (ESI): C21H21N3O3S [M + H]+ calcd,
396.1376; found, 396.1382.
</para>
<para sub=“exp”>
(2S,3S)-2-((2-Hydroxyethyl)thio)-4-nitro-3-phenyl-1-(1-phenyl-
1H-imidazol-2-yl)butan-1-one (3s). Colorless oil; 31.9 mg, 77% yield;
83% ee determined by HPLC on a Chiralpak OD-H column (hexane/2-
propanol = 60/40, ﬂow rate = 1.0 mL/min, tminor = 9.3 min, tmajor = 6.6
D = −88.8 (c = 0.98, CHCl3); 1H NMR (300 MHz, CDCl3) δ
min); [α]rt
= 7.43−7.29 (m, 4H), 7.22 (d, J = 10.9 Hz, 5H), 7.12 (s, 1H), 6.86 (d, J =
7.0 Hz, 2H), 5.41−5.28 (m, 2H), 4.88 (dd, J = 12.7, 10.4 Hz, 1H), 4.38
(s, 1H), 4.09 (td, J = 10.7, 4.2 Hz, 1H), 3.88 (s, 2H), 2.86 (t, J = 5.3 Hz,
2H) ppm; 13C NMR (75 MHz, CDCl3) = 184.1, 141.7, 137.5, 137.4,
129.5, 129.2, 129.1, 128.9, 128.3, 128.0, 127.5, 125.2, 78.8, 62.6, 49.7,
44.7, 35.3 ppm; IR (neat) 3343, 2923, 2370, 1677, 1596, 1550, 1382,
1068, 767, 697 cm−1; HRMS (ESI): C21H21N3O4S [M + H]+ calcd,
412.1326; found, 412.1331.
</para>
<para sub=“exp”>
(2S,3S)-4-Nitro-3-phenyl-1-(1-phenyl-1H-imidazol-2-yl)-2-(p-
tolyloxy)butan-1-one (4a). Colorless oil; 39.4 mg, 89% yield; 92% ee
determined by HPLC on a Chiralpak IA-H column (hexane/2-propanol
= 80/20, ﬂow rate = 1.0 mL/min, tminor = 8.1 min, tmajor = 12.1 min);
D = 10.9 (c = 1.00, CHCl3); 1H NMR (300 MHz, CDCl3) δ = 7.45−
[α]rt
7.33 (m, 5H), 7.33−7.22 (m, 4H), 7.10−7.02 (m, 2H), 6.98 (d, J = 8.4
Hz, 2H), 6.82 (d, J = 8.6 Hz, 2H), 6.29 (d, J = 5.1 Hz, 1H), 4.97 (m, J =
22.8, 13.6, 7.1 Hz, 2H), 4.45−4.22 (m, 1H), 2.21 (s, 3H) ppm; 13C
NMR (75 MHz, CDCl3) δ = 186.7, 155.1, 141.5, 137.4, 136.4, 131.2,
130.5, 130.0, 129.0, 128.8, 128.6, 128.2, 127.9, 125.7, 115.3, 79.2, 77.5,
46.5, 20.5 ppm; IR (neat) 3370, 2924, 2374, 1554, 1223, 760, 697, 520
cm−1; HRMS (ESI): C26H23N3O4 [M + H]+ calcd, 442.1761; found,
442.1773.
</para>
<para sub=“exp”>

(2S,3S)-3-(4-Fluorophenyl)-4-nitro-1-(1-phenyl-1H-imidazol-2-
yl)-2-(p-tolyloxy)butan-1-one (4b). Colorless oil; 39.2 mg, 85% yield;
91% ee determined by HPLC on a Chiralpak IA-H column (hexane/2-
propanol = 60/40, ﬂow rate = 1.0 mL/min, tminor = 6.1 min, tmajor = 8.4
D = 14.4 (c = 0.97, CHCl3); 1H NMR (300 MHz, CDCl3) δ =
min); [α]rt
7.46−7.35 (m, 5H), 7.33 (s, 1H), 7.21 (s, 1H), 7.11 (m, J = 6.3, 2.5 Hz,
2H), 6.98 (t, J = 8.0 Hz, 4H), 6.80 (d, J = 8.4 Hz, 2H), 6.24 (d, J = 4.8 Hz,
1H), 4.94 (m, J = 23.1, 13.6, 7.2 Hz, 2H), 4.34 (m, J = 9.5, 4.8 Hz, 1H),
2.22 (s, 3H). 13C NMR (75 MHz, CDCl3) δ = 186.4, 162.5 (d, J = 245.7
Hz), 154.9, 141.3, 137.3, 132.3 (d, J = 3.2 Hz), 131.4, 130.6, 130.3 (d, J =
8.2 Hz), 130.1, 129.1 (overlapped), 128.0, 125.7, 115.8 (d, J = 2.1 Hz),
115.2, 79.2, 76.1, 45.7, 20.5. IR (neat) 3364, 2925, 2367, 1693, 1555,
1510, 1229, 1107, 761, 694 cm−1; HRMS (ESI): C26H22FN3O4 [M +
H]+ calcd, 460.1667; found, 460.1687.
</para>
<para sub=“exp”>
(2S,3S)-3-(4-Chlorophenyl)-4-nitro-1-(1-phenyl-1H-imidazol-2-
yl)-2-(p-tolyloxy)butan-1-one (4c). Colorless oil; 40.0 mg, 84% yield;
90% ee determined by HPLC on a Chiralpak IA-H column (hexane/2-
propanol = 60/40, ﬂow rate = 1.0 mL/min, tminor = 6.5 min, tmajor = 7.5
D = 42.6 (c = 1.03, CHCl3); 1H NMR (300 MHz, CDCl3) δ =
min); [α]rt
7.44−7.31 (m, 6H), 7.25 (m, J = 10.5, 7.8 Hz, 3H), 7.16−7.07 (t, 2H),
6.99 (d, J = 8.3 Hz, 2H), 6.79 (d, J = 8.5 Hz, 2H), 6.23 (d, J = 4.5 Hz,
1H), 4.94 (m, J = 13.8, 7.2 Hz, 2H), 4.34 (m, J = 9.4, 4.7 Hz, 1H), 2.21 (s,
3H) ppm; 13C NMR (75 MHz, CDCl3) δ = 186.2, 154.8, 141.2, 137.2,
135.1, 134.1, 131.3, 130.5, 130.0, 129.8, 128.99, 128.96, 128.0, 125.6,
115.1, 79.1, 75.7, 45.6, 20.4 ppm; IR (neat) 3366, 2925, 2373, 1694,
1555, 1509, 1403, 1219, 759, 694 cm−1; HRMS (ESI): C26H22ClN3O4
[M + H]+ calcd, 476.1372; found, 476.1392.
</para>
<para sub=“exp”>
(2S,3S)-3-(4-Bromophenyl)-4-nitro-1-(1-phenyl-1H-imidazol-2-
yl)-2-(p-tolyloxy)butan-1-one (4d). Colorless oil; 42.6 mg, 82% yield;
93% ee determined by HPLC on a Chiralpak IA-H column (hexane/2-
</para>
4344

DOI: 10.1021/acs.joc.5b00013
J. Org. Chem. 2015, 80, 4336−4348

The Journal of Organic Chemistry

Article
<para sub=“exp”>
propanol = 60/40, ﬂow rate = 1.0 mL/min, tminor = 6.4 min, tmajor = 7.0
D = 43.5 (c = 0.97, CHCl3); 1H NMR (300 MHz, CDCl3) δ =
min); [α]rt
7.40 (m, J = 9.5, 6.4 Hz, 5H), 7.32 (m, J = 14.0, 5.8 Hz, 3H), 7.22 (s, 1H),
7.16−7.07 (m, 2H), 6.99 (d, J = 8.4 Hz, 2H), 6.79 (d, J = 8.5 Hz, 2H),
6.22 (d, J = 4.5 Hz, 1H), 4.94 (m, J = 13.8, 7.2 Hz, 2H), 4.32 (m, J = 9.3,
4.7 Hz, 1H), 2.22 (s, 3H) ppm; 13C NMR (75 MHz, CDCl3) δ = 186.3,
154.9, 141.2, 137.3, 135.7, 132.0, 131.4, 130.6, 130.3, 130.1, 129.1, 128.1,
125.7, 122.4, 115.2, 79.2, 75.7, 45.8, 20.5 ppm; IR (neat) 3367, 2925,
2371, 1695, 1555, 1509, 1403, 1229, 1013, 759, 694 cm−1; HRMS (ESI):
C26H22BrN3O4 [M + H]+ calcd, 520.0866; found, 520.0888.
</para>
<para sub=“exp”>
(2S,3S)-4-Nitro-1-(1-phenyl-1H-imidazol-2-yl)-3-(p-tolyl)-2-(p-
tolyloxy)butan-1-one (4e). Colorless oil; 36.4 mg, 80% yield; 90% ee
determined by HPLC on a Chiralpak IA-H column (hexane/2-propanol
= 60/40, ﬂow rate = 1.0 mL/min, tminor = 5.9 min, tmajor = 6.5 min); [α]rt
D
= 20.7 (c = 0.96, CHCl3); 1H NMR (300 MHz, CDCl3) δ = 7.42−7.34
(m, 3H), 7.32 (s, 1H), 7.27 (t, J = 6.9 Hz, 2H), 7.18 (d, J = 0.6 Hz, 1H),
7.13−7.02 (m, 4H), 6.98 (d, J = 8.4 Hz, 2H), 6.25 (d, J = 5.0 Hz, 1H),
4.95 (qd, J = 13.5, 7.2 Hz, 2H), 4.30 (dt, J = 9.6, 5.0 Hz, 1H), 2.28 (s,
3H), 2.23 (d, J = 7.8 Hz, 3H) ppm; 13C NMR (75 MHz, CDCl3) δ =
186.8, 155.1, 141.5, 137.9, 137.4, 133.3, 131.2, 130.4, 130.0, 129.5, 129.0,
128.9, 128.4, 127.8, 125.7, 115.2, 79.3, 76.4, 46.1, 21.1, 20.5 ppm; IR
(neat) 3366, 2924, 1879, 1692, 1554, 1510, 1403, 1229, 758, 694 cm−1;
HRMS (ESI): C27H25N3O4 [M + H]+ calcd, 456.1918; found, 456.1922.
(2S,3S)-3-(4-Methoxyphenyl)-4-nitro-1-(1-phenyl-1H-imidazol-2-
yl)-2-(p-tolyloxy)butan-1-one (4f). Colorless oil; 44.4 mg, 94% yield;
86% ee determined by HPLC on a Chiralpak OD-H column (hexane/2-
propanol = 60/40, ﬂow rate = 1.0 mL/min, tminor = 8.5 min, tmajor = 12.7
D = 25.2 (c = 1.03, CHCl3); 1H NMR (300 MHz, CDCl3) δ =
min); [α]rt
7.38 (m, J = 8.6, 3.1 Hz, 3H), 7.32 (m, J = 7.8, 5.3 Hz, 3H), 7.17 (s, 1H),
7.06 (m, J = 4.5, 3.3 Hz, 2H), 6.98 (d, J = 8.4 Hz, 2H), 6.82 (t, J = 8.7 Hz,
4H), 6.25 (d, J = 5.3 Hz, 1H), 4.93 (m, J = 22.8, 13.4, 7.2 Hz, 2H), 4.28
(m, J = 9.7, 5.0 Hz, 1H), 3.74 (s, 3H), 2.21 (s, 3H) ppm; 13C NMR (75
MHz, CDCl3) δ = 186.9, 159.4, 155.1, 141.5, 137.4, 131.2, 130.5, 130.0,
129.7, 129.0, 128.2, 127.9, 125.7, 115.2, 114.2, 79.3, 76.6, 55.3, 45.9, 20.5
ppm; IR (neat) 3301, 2925, 2373, 1690, 1553, 1511, 1253, 1033, 762,
695 cm−1; HRMS (ESI): C27H25N3O5 [M + H]+ calcd, 472.1867; found,
472.1872.
</para>
<para sub=“exp”>
(2S,3S)-3-(3-Chlorophenyl)-4-nitro-1-(1-phenyl-1H-imidazol-2-
yl)-2-(p-tolyloxy)butan-1-one (4g). Colorless oil; 37.7 mg, 79% yield;
88% ee determined by HPLC on a Chiralpak OD-H column (hexane/2-
propanol = 60/40, ﬂow rate = 1.0 mL/min, tminor = 7.0 min, tmajor = 8.7
D = 22.3 (c = 0.99, CHCl3); 1H NMR (300 MHz, CDCl3) δ =
min); [α]rt
7.44−7.37 (m, 4H), 7.36−7.29 (m, 2H), 7.25−7.21 (m, 2H), 7.20 (d, J =
0.9 Hz, 1H), 7.11 (m, J = 4.4, 3.5 Hz, 2H), 6.99 (d, J = 8.3 Hz, 2H),
6.84−6.77 (m, 2H), 6.25 (d, J = 4.8 Hz, 1H), 5.01 (dd, J = 13.9, 4.9 Hz,
1H), 4.90 (dd, J = 13.9, 9.4 Hz, 1H), 4.31 (dt, J = 9.5, 4.9 Hz, 1H), 2.22
(s, 3H) ppm; 13C NMR (75 MHz, CDCl3) δ = 186.2, 154.9, 141.3,
138.5, 137.3, 134.6, 131.4, 130.6, 130.1, 130.0, 129.1, 129.0, 128.5, 128.1,
126.7, 125.7, 115.2, 78.9, 75.7, 46.1, 20.5 ppm; IR (neat) 3359, 2925,
2370, 1694, 1555, 1509, 1403, 1219, 1089, 762, 694 cm−1; HRMS (ESI):
C26H22ClN3O4 [M + H]+ calcd, 476.1372; found, 476.1377.
</para>
<para sub=“exp”>
(2S,3S)-4-Nitro-2-phenoxy-1-(1-phenyl-1H-imidazol-2-yl)-3-(m-
tolyl)butan-1-one (4h). Colorless oil; 30.2 mg, 66% yield; 87% ee
determined by HPLC on a Chiralpak OD-H column (hexane/2-
propanol = 60/40, ﬂow rate = 1.0 mL/min, tminor = 6.1 min, tmajor = 7.1
D = 9.9 (c = 1.01, CHCl3); 1H NMR (300 MHz, CDCl3) δ =
min); [α]rt
7.41−7.30 (m, 4H), 7.16 (d, J = 6.6 Hz, 4H), 7.02 (m, J = 6.9, 3.8, 1.8 Hz,
4H), 6.97 (s, 1H), 6.86 (d, J = 5.6 Hz, 2H), 6.29 (d, J = 5.5 Hz, 1H), 5.02
(dd, J = 13.5, 5.0 Hz, 1H), 4.90 (dd, J = 13.5, 9.3 Hz, 1H), 4.36−4.18 (m,
1H), 2.29 (s, 3H), 2.21 (s, 3H) ppm; 13C NMR (75 MHz, CDCl3) δ =
186.8, 155.0, 141.6, 138.4, 137.3, 136.0, 131.1, 130.3, 129.9, 129.4, 128.9,
128.6, 127.7, 125.6, 115.2, 78.9, 76.4, 46.5, 21.3, 20.4 ppm; IR (neat)
3364, 2924, 2374, 1695, 1555, 1509, 1403, 1228, 760, 695 cm−1; HRMS
(ESI): C27H25N3O4 [M + H]+ calcd, 456.1918; found, 456.1923.
(2S,3S)-3-(2-Fluorophenyl)-4-nitro-1-(1-phenyl-1H-imidazol-2-
yl)-2-(p-tolyloxy)butan-1-one (4i). White solid, mp 103−105 °C; 27.1
mg, 59% yield; 87% ee determined by HPLC on a Chiralpak IA-H
column (hexane/2-propanol = 60/40, ﬂow rate = 1.0 mL/min, tminor =
6.4 min, tmajor = 9.9 min); [α]rt
D = 5.1 (c = 0.99, CHCl3); 1H NMR (300
MHz, CDCl3) δ = 7.46−7.34 (m, 4H), 7.34−7.17 (m, 3H), 7.15 (s, 1H),
</para>
<para sub=“exp”>
7.06 (m, J = 5.5, 3.9 Hz, 3H), 7.00 (d, J = 8.7 Hz, 3H), 6.85 (d, J = 8.5 Hz,
2H), 6.36 (d, J = 6.4 Hz, 1H), 5.09 (dd, J = 13.7, 5.2 Hz, 1H), 4.96 (dd, J
= 13.7, 8.9 Hz, 1H), 4.60 (m, J = 9.0, 5.8 Hz, 1H), 2.22 (s, 3H). 13C NMR
(75 MHz, CDCl3) δ = 186.5, 161.0 (d, J = 246.3 Hz), 154.9, 141.5,
137.4, 131.3, 130.6 (d, J = 4.0 Hz), 130.5, 130.1 (J = 8.2 Hz), 130.0,
129.0, 127.9, 125.7, 124.5 (J = 3.8 Hz), 123.0 (d, J = 14.3 Hz), 116.0 (J =
21.8 Hz), 115.1, 77.5, 75.3 (overlapped), 41.2, 20.5. IR (neat) 3367,
2963, 2407, 1693, 1556, 1403, 1221, 1110, 759, 694 cm−1; HRMS (ESI):
C26H22FN3O4 [M + H]+ calcd, 460.1667; found, 460.1672.
</para>
<para sub=“exp”>
(2S,3S)-3-(Naphthalen-2-yl)-4-nitro-1-(1-phenyl-1H-imidazol-2-
yl)-2-(p-tolyloxy)butan-1-one (4j). Colorless oil; 31.3 mg, 64% yield;
85% ee determined by HPLC on a Chiralpak IA-H column (hexane/2-
propanol = 80/20, ﬂow rate = 1.0 mL/min, tminor = 10.4 min, tmajor = 11.3
D = 62.7 (c = 1.00, CHCl3); 1H NMR (300 MHz, CDCl3) δ =
min); [α]rt
7.77 (m, J = 10.2, 5.2 Hz, 4H), 7.55 (dd, J = 8.5, 1.3 Hz, 1H), 7.49−7.42
(m, 2H), 7.35 (m, J = 16.8, 9.7, 4.1 Hz, 4H), 7.08 (s, 1H), 6.98 (d, J = 8.5
Hz, 2H), 6.89 (m, J = 13.5, 7.9 Hz, 4H), 6.39 (d, J = 5.4 Hz, 1H), 5.07
(m, J = 13.6, 7.2 Hz, 2H), 4.56−4.43 (m, 1H), 2.21 (s, 3H) ppm; 13C
NMR (75 MHz, CDCl3) δ = 186.7, 155.1, 141.6, 137.2, 133.5, 133.3,
133.0, 131.3, 130.4, 130.0, 129.0, 128.9, 128.6, 128.2, 128.0, 127.9, 127.6,
126.4, 125.9, 125.7, 115.3, 79.1, 76.3, 46.8, 20.5 ppm; IR (neat) 3298,
2924, 2405, 1690, 1553, 1510, 1223, 1016, 759, 694 cm−1; HRMS (ESI):
C30H25N3O4 [M + H]+ calcd, 492.1918; found, 492.1926.
</para>
<para sub=“exp”>
(2S,3S)-3-(Furan-2-yl)-4-nitro-1-(1-phenyl-1H-imidazol-2-yl)-2-(p-
tolyloxy)butan-1-one (4k). Colorless oil; 32.5 mg, 75% yield; 80% ee
determined by HPLC on a Chiralpak IA-H column (hexane/2-propanol
= 60/40, ﬂow rate = 1.0 mL/min, tminor = 5.9 min, tmajor = 7.6 min); [α]rt
D
= 14.1 (c = 1.00, CHCl3); 1H NMR (300 MHz, CDCl3) δ = 7.56−7.38
(m, 3H), 7.32 (s, 2H), 7.24−7.11 (m, 3H), 6.99 (d, J = 8.4 Hz, 2H), 6.82
(d, J = 8.5 Hz, 2H), 6.37 (d, J = 5.8 Hz, 1H), 6.23 (s, 2H), 4.95 (qd, J =
13.8, 6.9 Hz, 2H), 4.52 (dt, J = 8.3, 5.5 Hz, 1H), 2.23 (d, J = 6.7 Hz, 3H)
ppm; 13C NMR (75 MHz, CDCl3) δ = 186.3, 155.0, 149.2, 142.8, 141.3,
137.4, 131.3, 130.6, 130.0, 129.1, 128.0, 125.7, 115.2, 115.2, 110.5, 77.5,
74.1, 40.7, 20.5 ppm; IR (neat) 3369, 2924, 2450, 1695, 1556, 1509,
1404, 1229, 760, 694 cm−1; HRMS (ESI): C24H21N3O5 [M + H]+ calcd,
432.1554; found, 432.1558.
</para>
<para sub=“exp”>
(2S,3S)-4-Nitro-2-phenoxy-1-(1-phenyl-1H-imidazol-2-yl)-3-(thio-
phen-2-yl)butan-1-one (4l). Colorless oil; 31.4 mg, 70% yield; >99% ee
determined by HPLC on a Chiralpak IA-H column (hexane/2-propanol
= 80/20, ﬂow rate = 1.0 mL/min, tminor = 9.3 min, tmajor = 10.5 min);
D = −13.4 (c = 0.97, CHCl3); 1H NMR (300 MHz, CDCl3) δ =
[α]rt
7.46−7.38 (m, 3H), 7.38−7.33 (d, 1H), 7.25 (s, J = 0.9 Hz, 1H), 7.22−
7.14 (m, 3H), 7.09−7.04 (t, 1H), 7.00 (d, J = 8.3 Hz, 2H), 6.91 (dd, J =
5.1, 3.5 Hz, 1H), 6.83 (d, J = 5.7 Hz, 2H), 6.29 (d, J = 3.7 Hz, 1H), 4.97
(dd, J = 13.4, 4.5 Hz, 1H), 4.83 (dd, J = 13.3, 8.9 Hz, 1H), 4.74 (m, J =
8.6, 4.2 Hz, 1H), 2.23 (s, 3H) ppm; 13C NMR (75 MHz, CDCl3) δ =
186.0, 154.8, 141.2, 138.6, 137.4, 131.4, 130.7, 130.0, 129.1, 128.1, 127.2,
126.7, 125.9, 125.7, 115.2, 79.4, 76.8, 42.0, 20.5 ppm; IR (neat) 3343,
2925, 2373, 1694, 1556, 1403, 1218, 1040, 763, 699 cm−1; HRMS (ESI):
C24H21N3O4S [M + H]+ calcd, 448.1326; found, 448.1332.
</para>
<para sub=“exp”>
(2S,3S)-3-(3,5-Dimethoxyphenyl)-4-nitro-1-(1-phenyl-1H-imida-
zol-2-yl)-2-(p-tolyloxy)butan-1-one (4m). Colorless oil; 31.5 mg, 63%
yield; 76% ee determined by HPLC on a Chiralpak IA-H column
(hexane/2-propanol = 60/40, ﬂow rate = 1.0 mL/min, tminor = 6.0 min,
tmajor = 6.7 min); [α]rt
D = 12.9 (c = 1.00, CHCl3); 1H NMR (300 MHz,
CDCl3) δ = 7.47−7.27 (m, 5H), 7.17 (d, J = 0.7 Hz, 1H), 7.06 (m, J =
7.0, 3.1 Hz, 2H), 6.99 (d, J = 8.4 Hz, 2H), 6.85 (m, J = 8.2, 6.0 Hz, 2H),
6.52 (d, J = 2.2 Hz, 2H), 6.38−6.23 (m, 2H), 4.95 (m, J = 22.7, 13.6, 7.1
Hz, 2H), 4.31−4.10 (m, 1H), 3.72 (s, 6H), 2.22 (s, 3H) ppm; 13C NMR
(75 MHz, CDCl3) δ = 186.7, 160.9, 155.0, 141.7, 138.3, 137.3, 131.2,
130.4, 130.0, 129.0, 127.8, 125.7, 115.2, 114.5, 106.7, 100.3, 78.8, 76.3,
55.3, 46.8, 20.5 ppm; IR (neat) 3370, 2927, 2450, 1695, 1597, 1555,
1229, 1155, 759, 694 cm−1; HRMS (ESI): C28H27N3O6 [M + H]+ calcd,
502.1973; found, 502.1979.
(2S,3S)-3-(Nitromethyl)-1-(1-phenyl-1H-imidazol-2-yl)-2-(p-
tolyloxy)nonan-1-one (4n). White solid, mp 92−94 °C; 24.1 mg, 54%
yield; 86% ee determined by HPLC on a Chiralpak IC-H column
(hexane/2-propanol = 90/10, ﬂow rate = 1.0 mL/min, tminor = 6.0 min,
tmajor = 9.5 min); [α]rt
D = 1.9 (c = 1.07, CHCl3); 1H NMR (300 MHz,
CDCl3) δ = 7.50−7.38 (m, 3H), 7.36 (s, 1H), 7.33−7.21 (m, 3H), 7.02
</para>
4345

DOI: 10.1021/acs.joc.5b00013
J. Org. Chem. 2015, 80, 4336−4348

The Journal of Organic Chemistry
<para sub=“exp”>
(d, J = 13.8 Hz, 2H), 6.76 (d, J = 8.2 Hz, 2H), 6.18 (s, 1H), 4.70 (dd, J =
13.9, 4.3 Hz, 1H), 4.42 (dd, J = 13.8, 7.5 Hz, 1H), 3.09 (s, 1H), 2.23 (s,
3H), 1.84−1.70 (m, 1H), 1.66−1.45 (m, 4H), 1.28 (m, 6H), 0.87 (m, J =
6.5 Hz, 3H) ppm; 13C NMR (75 MHz, CDCl3) δ = 186.4, 154.2, 140.1,
136.5, 129.8, 129.4, 128.9, 128.1, 128.0, 126.9, 124.7, 113.8, 74.6, 39.0,
30.5, 29.5, 28.0, 25.4, 21.6, 19.4, 13.0, 0.0 ppm; IR (neat) 3369, 2927,
2857, 2366, 1696, 1553, 1509, 1233, 760, 694 cm−1; HRMS (ESI):
C26H31N3O4 [M + H]+ calcd, 450.2387; found, 450.2395.
</para>
<para sub=“exp”>
(2S,3S)-4-Methyl-3-(nitromethyl)-1-(1-phenyl-1H-imidazol-2-yl)-
2-(p-tolyloxy)pentan-1-one (4o). White solid, mp 151−153 °C; 21.7
mg, 53% yield; 94% ee determined by HPLC on a Chiralpak OD-H
column (hexane/2-propanol = 60/40, ﬂow rate = 1.0 mL/min, tminor =
D = −8.5(c = 0.94, CHCl3); 1H NMR (300
7.1 min, tmajor = 6.1 min); [α]rt
MHz, CDCl3) δ = 7.54−7.34 (m, 4H), 7.27 (m, J = 6.0, 3.3 Hz, 3H), 6.99
(d, J = 8.2 Hz, 2H), 6.83−6.68 (m, 2H), 6.30 (d, J = 1.6 Hz, 1H), 4.80
(dd, J = 14.6, 4.1 Hz, 1H), 4.51 (dd, J = 14.6, 6.6 Hz, 1H), 2.94 (m, J =
6.5, 4.6 Hz, 1H), 2.22 (s, 3H), 2.06 (m, J = 13.1, 6.7 Hz, 1H), 1.12 (m, J =
6.7, 2.9 Hz, 6H) ppm; 13C NMR (75 MHz, CDCl3) δ = 187.6, 154.8,
141.0, 137.6, 130.8, 130.4, 130.0, 129.1, 129.0, 128.0, 125.8, 114.6, 73.8,
45.3, 30.3, 20.5, 20.3, 19.7 ppm; IR (neat) 3368, 2964, 2407, 1695, 1553,
1510, 1403, 1233, 761, 694 cm−1; HRMS (ESI): C23H25N3O4 [M + H]+
calcd, 408.1918; found, 408.1924.
</para>
<para sub=“exp”>
(2S,3S)-4-Nitro-2-phenoxy-3-phenyl-1-(1-phenyl-1H-imidazol-2-
yl)butan-1-one (4p). White solid, mp 122−124 °C; 30.6 mg, 71% yield;
88% ee determined by HPLC on a Chiralpak IA-H column (hexane/2-
propanol = 60/40, ﬂow rate = 1.0 mL/min, tminor = 5.2 min, tmajor = 7.6
D = 27.4 (c = 0.95, CHCl3); 1H NMR (300 MHz, CDCl3) δ =
min); [α]rt
7.44−7.34 (m, 5H), 7.34−7.23 (m, 4H), 7.23−7.15 (m, 3H), 7.10−7.04
(m, 2H), 6.92 (m, J = 12.3, 4.5 Hz, 3H), 6.34 (d, J = 5.0 Hz, 1H), 4.98
(qd, J = 13.6, 7.1 Hz, 2H), 4.48−4.25 (m, 1H) ppm; 13C NMR (75 MHz,
CDCl3) δ = 186.5, 157.1, 141.4, 137.3, 136.3, 130.5, 129.6, 129.0, 128.9,
128.6, 128.3, 127.9, 125.7, 121.9, 115.3, 79.0, 76.2, 46.3 ppm; IR (neat)
3369, 2925, 2408, 1694, 1596, 1554, 1403, 1227, 754,695 cm−1; HRMS
(ESI): C25H21N3O4 [M + H]+ calcd, 428.1605; found, 428.1610.
</para>
<para sub=“exp”>
(2S,3S)-2-(2-Methoxyphenoxy)-4-nitro-3-phenyl-1-(1-phenyl-1H-
imidazol-2-yl)butan-1-one (4q). Colorless oil; 30.8 mg, 67% yield; 92%
ee determined by HPLC on a Chiralpak OD-H column (hexane/2-
propanol = 60/40, ﬂow rate = 1.0 mL/min, tminor = 9.7 min, tmajor = 7.1
D = −17.2 (c = 0.93, CHCl3); 1H NMR (300 MHz, CDCl3) δ
min); [α]rt
= 7.46−7.34 (m, 5H), 7.31−7.20 (m, 4H), 7.15 (s, 1H), 7.11−6.97 (m,
2H), 6.96−6.80 (m, 3H), 6.78−6.65 (m, 1H), 6.24 (d, J = 5.7 Hz, 1H),
5.18 (dd, J = 13.7, 4.6 Hz, 1H), 5.01 (dd, J = 13.7, 9.9 Hz, 1H), 4.35 (dt, J
= 10.1, 5.0 Hz, 1H), 3.77 (s, 3H) ppm; 13C NMR (75 MHz, CDCl3) δ =
186.5, 150.2, 146.7, 141.7, 137.5, 136.3, 130.4, 129.9, 128.8, 128.7, 128.1,
127.7, 125.7, 123.0, 120.7, 116.8, 112.6, 80.3, 76.4, 55.9, 46.7 ppm; IR
(neat) 3363, 2924, 2378, 1690, 1553, 1501, 1381, 1257, 1025, 759, 698
cm−1; HRMS (ESI): C26H23N3O5 [M + H]+ calcd, 458.1710; found,
458.1720.
</para>
<para sub=“exp”>
(2S,3S)-2-(3-Chlorophenoxy)-4-nitro-3-phenyl-1-(1-phenyl-1H-
imidazol-2-yl)butan-1-one (4r). White solid, mp 120−122 °C; 31.5
mg, 68% yield; 90% ee determined by HPLC on a Chiralpak IA-H
column (hexane/2-propanol = 60/40, ﬂow rate = 1.0 mL/min, tminor =
10.8 min, tmajor = 13.9 min); [α]rt
D = 13.1 (c = 1.07, CHCl3); 1H NMR
(300 MHz, CDCl3) δ = 7.44−7.36 (m, 5H), 7.35 (s, 1H), 7.31 (m, J =
11.1, 4.9 Hz, 3H), 7.21 (s, 1H), 7.09 (m, J = 7.8, 6.2 Hz, 3H), 6.98 (t, J =
2.1 Hz, 1H), 6.90 (d, J = 7.8 Hz, 1H), 6.81 (dd, J = 8.3, 2.4 Hz, 1H), 6.32
(d, J = 5.0 Hz, 1H), 4.96 (m, J = 13.6, 7.1 Hz, 2H), 4.43−4.31 (m, 1H)
ppm; 13C NMR (75 MHz, CDCl3) δ = 185.9, 157.7, 141.4, 137.2, 136.1,
135.0, 130.6, 130.4, 129.1, 129.0, 128.9, 128.5, 128.4, 128.1, 125.7, 122.2,
116.2, 113.4, 79.2, 75.9, 46.4 ppm; IR (neat) 3369, 2962, 2374, 1692,
1555, 1381, 1222, 1092, 767, 698 cm−1; HRMS (ESI): C25H20ClN3O4
[M + H]+ calcd, 462.1215; found, 462.1220.
(2S,3S)-2-(Naphthalen-2-yloxy)-4-nitro-3-phenyl-1-(1-phenyl-1H-
imidazol-2-yl)butan-1-one (4s). White solid, mp 167−169 °C; 34.7
mg, 73% yield; 83% ee determined by HPLC on a Chiralpak OD-H
column (hexane/2-propanol = 60/40, ﬂow rate = 1.0 mL/min, tminor =
D = −60.4 (c = 1.06, CHCl3); 1H NMR
8.6 min, tmajor = 9.7 min); [α]rt
(300 MHz, CDCl3) δ = 7.75−7.66 (m, 2H), 7.58 (d, J = 8.0 Hz, 1H),
7.45−7.38 (m, 3H), 7.37 (s, 3H), 7.35−7.28 (m, 4H), 7.25 (d, J = 7.1
Hz, 2H), 7.23−7.15 (m, 2H), 7.08−6.97 (m, 2H), 6.50 (d, J = 5.3 Hz,
</para>
Article
<para sub=“exp”>
1H), 5.03 (ddd, J = 22.7, 13.6, 7.1 Hz, 2H), 4.52−4.34 (m, 1H) ppm; 13C
NMR (75 MHz, CDCl3) δ = 186.5, 155.0, 141.6, 137.4, 137.3, 136.2,
134.1, 130.5, 129.8, 129.5, 129.0, 128.9, 128.6, 128.3, 128.0, 127.6, 127.0,
126.4, 125.7, 124.1, 118.6, 108.6, 79.0, 76.3, 46.5 ppm; IR (neat) 3368,
2962, 2398, 1692, 1555, 1380, 1258, 1216, 757, 697 cm−1; HRMS (ESI):
C29H23N3O4 [M + H]+ calcd, 478.1761; found, 478.1767
</para>
<para sub=“exp”>
(2S,3S)-4-Nitro-1-oxo-3-phenyl-1-(1-phenyl-1H-imidazol-2-yl)-
butan-2-yl Acetate (4t). Colorless oil; 26.3 mg, 67% yield; 90% ee
determined by HPLC on a Chiralpak IA-H column (hexane/2-propanol
= 60/40, ﬂow rate = 1.0 mL/min, tminor = 5.6 min, tmajor = 9.9 min); [α]rt
D
= 99.0 (c = 1.05, CHCl3); 1H NMR (300 MHz, CDCl3) δ = 7.46 (m, J =
6.5, 3.8 Hz, 3H), 7.43−7.36 (m, 3H), 7.35 (s, 2H), 7.32 (m, J = 2.3 Hz,
1H), 7.22 (m, J = 6.8, 2.7 Hz, 3H), 6.37 (d, J = 3.6 Hz, 1H), 4.94−4.77
(m, 2H), 4.49 (m, J = 9.0, 5.6, 3.6 Hz, 1H), 2.10 (s, 3H) ppm; 13C NMR
(75 MHz, CDCl3) δ = 184.2, 169.7, 140.7, 137.6, 136.5, 130.6, 129.1,
129.0, 128.9, 128.3, 128.2, 127.7, 125.8, 77.0, 75.0, 44.4, 20.4 ppm; IR
(neat) 3376, 2962, 2445, 1749, 1697, 1556, 1405, 1228, 759, 698 cm−1;
HRMS (ESI): C21H19N3O5 [M + H]+ calcd, 394.1397; found, 394.1402.
</para>
<para sub=“exp”>
(2S,3S)-2-Chloro-4-nitro-3-phenyl-1-(1-phenyl-1H-imidazol-2-yl)-
butan-1-one (5a). White solid, mp 146−148 °C; 36.4 mg, 88% yield
(4.0:1 dr); 95%/97% ee determined by HPLC on a Chiralpak OD-H
column (hexane/2-propanol = 60/40, ﬂow rate = 1.0 mL/min, tminor =
9.3/10.2 min, tmajor = 8.1/11.6 min); [α]rt
D = 43.8 (c = 1.00, CHCl3); 1H
NMR (300 MHz, CDCl3) δ = 7.41 (m, J = 5.6, 3.7 Hz, 3H), 7.30−7.24
(m, 6H), 7.18 (d, J = 0.7 Hz, 1H), 6.99 (dd, J = 7.9, 1.6 Hz, 2H), 6.12 (d,
J = 9.5 Hz, 1H), 5.13 (dd, J = 13.2, 4.4 Hz, 1H), 4.87 (dd, J = 13.2, 10.1
Hz, 1H), 4.31 (m, J = 9.8, 4.4 Hz, 1H) ppm; 13C NMR (75 MHz,
CDCl3) δ = 181.8, 140.9, 137.3, 135.3, 130.6, 129.12, 129.11, 129.0,
128.6, 128.5, 125.4, 59.7, 57.9, 46.3 ppm; IR (neat) 3370, 2925, 2366,
1696, 1556, 1403, 1217, 1090, 761, 696 cm−1; HRMS (ESI):
C19H16ClN3O3 [M + H]+ calcd, 370.0953; found, 370.0959.
</para>
<para sub=“exp”>
(2S,3S)-2-Chloro-3-(4-chlorophenyl)-4-nitro-1-(1-phenyl-1H-imi-
dazol-2-yl)butan-1-one (5b). White solid, mp 133−135 °C; 32 mg,
79% yield (3.6:1 dr); 81% ee determined by HPLC on a Chiralpak IA-H
column (hexane/2-propanol = 40/60, ﬂow rate = 1.0 mL/min, tminor =
6.5 min, tmajor = 15.3 min); [α]rt
D = 91.3 (c = 1.03, CHCl3); 1H NMR
(300 MHz, CDCl3) δ = 7.49−7.39 (m, 3H), 7.30 (d, J = 0.8 Hz, 1H),
7.26−7.20 (m, 4H), 7.11−7.04 (m, 2H), 6.07 (d, J = 9.3 Hz, 1H), 5.11
(dd, J = 13.3, 4.4 Hz, 1H), 4.83 (dd, J = 13.3, 10.2 Hz, 1H), 4.30 (td, J =
9.8, 4.3 Hz, 1H) ppm; 13C NMR (75 MHz, CDCl3) δ = 181.5, 140.7,
137.2, 134.5, 133.9, 130.7, 129.9, 129.2,129.1,128.7, 125.4, 77.2, 57.7,
45.5 ppm; IR (neat) 3365, 2925, 2370, 1695, 1556, 1402, 1380, 1095,
759, 694 cm−1; HRMS (ESI): C19H15Cl2N3O3 [M + H]+ calcd,
404.0563; found, 404.0569.
</para>
<para sub=“exp”>
(2S,3S)-2-Chloro-4-nitro-1-(1-phenyl-1H-imidazol-2-yl)-3-(p-
tolyl)butan-1-one (5c). White solid, mp 117−119 °C; 29.5 mg, 77%
yield; 96% ee determined by HPLC on a Chiralpak IA-H column
(hexane/2-propanol = 60/40, ﬂow rate = 1.0 mL/min, tminor = 6.5 min,
tmajor = 10.6 min); [α]rt
D = 62.4 (c = 0.98, CHCl3); 1H NMR (300 MHz,
CDCl3) δ = 7.46−7.39 (m, 3H), 7.29 (s, 1H), 7.18 (d, J = 3.5 Hz, 2H),
7.15 (s, 1H), 7.10 (d, J = 5.4 Hz, 2H), 7.00 (dd, J = 7.8, 1.6 Hz, 2H), 6.08
(d, J = 9.5 Hz, 1H), 5.10 (dd, J = 13.1, 4.4 Hz, 1H), 4.84 (dd, J = 13.1,
10.1 Hz, 1H), 4.27 (td, J = 9.8, 4.4 Hz, 1H), 2.27 (s, 3H) ppm; 13C NMR
(75 MHz, CDCl3) δ = 181.9, 140.9, 138.3, 137.3, 132.2, 130.6, 129.7,
129.1, 129.0, 128.4, 125.4, 77.7, 57.9, 45.9, 21.1 ppm; IR (neat) 3341,
2925, 2373, 1696, 1556, 1402, 1380, 1020, 760, 693 cm−1; HRMS (ESI):
C20H18ClN3O3 [M + H]+ calcd, 384.1109; found, 384.1116.
</para>
<para sub=“exp”>
(2S,3S)-2-Chloro-3-(3-chlorophenyl)-4-nitro-1-(1-phenyl-1H-imi-
dazol-2-yl)butan-1-one (5d). White solid, mp 131−133 °C; 25.9 mg,
64% yield (8.6:1 dr); 82% ee determined by HPLC on a Chiralpak IA-H
column (hexane/2-propanol = 60/40, ﬂow rate = 1.0 mL/min, tminor =
6.4 min, tmajor = 12.4 min); [α]rt
D = 62.8 (c = 1.02, CHCl3); 1H NMR
(300 MHz, CDCl3) δ = 7.52−7.40 (m, 3H), 7.30 (dd, J = 3.6, 1.1 Hz,
2H), 7.25−7.18 (m, 4H), 7.12−7.01 (m, 2H), 6.08 (d, J = 9.0 Hz, 1H),
5.12 (dd, J = 13.5, 4.3 Hz, 1H), 4.85 (dd, J = 13.5, 10.1 Hz, 1H), 4.34−
4.20 (m, 1H) ppm; 13C NMR (75 MHz, CDCl3) δ = 181.5, 140.7, 137.4,
137.2, 134.8, 130.7, 130.2, 129.2, 129.1, 128.8, 128.7, 126.4, 125.4, 76.9,
57.8, 45.8 ppm; IR (neat) 3366, 2924, 2403, 1695, 1556, 1402, 1217,
1019, 760, 693 cm−1; HRMS (ESI): C19H15Cl2N3O3 [M + H]+ calcd,
404.0563; found, 404.0569.
</para>
4346

DOI: 10.1021/acs.joc.5b00013
J. Org. Chem. 2015, 80, 4336−4348

The Journal of Organic Chemistry

Article
<para sub=“exp”>
(2S,3S)-2-Chloro-3-(2-ﬂuorophenyl)-4-nitro-1-(1-phenyl-1H-imi-
dazol-2-yl)butan-1-one (5e). Colorless oil; 20.1 mg, 52% yield; 87% ee
determined by HPLC on a Chiralpak IA-H column (hexane/2-propanol
= 60/40, ﬂow rate = 1.0 mL/min, tminor = 6.9 min, tmajor = 13.6 min);
D = 20.5 (c = 1.08, CHCl3); 1H NMR (300 MHz, CDCl3) δ = 7.42
[α]rt
(d, J = 7.2 Hz, 2H), 7.31 (s, 1H), 7.29−7.22 (m, 3H), 7.21 (s, J = 3.1 Hz,
1H), 7.10−6.99 (m, 4H), 6.24 (d, J = 9.9 Hz, 1H), 5.16 (dd, J = 13.4, 4.5
Hz, 1H), 5.09−4.94 (dd, 2H), 4.47 (td, J = 9.7, 4.6 Hz, 1H). 13C NMR
(75 MHz, CDCl3) δ = 181.7, 160.8 (d, J = 246.3 Hz), 140.7, 137.3, 131.3
(d, J = 4.1 Hz), 130.7, 130.4 (d, J = 8.5 Hz), 129.2, 129.1, 128.5, 125.3,
124.6 (d, J = 3.4 Hz), 122.2 (d, J = 13.2 Hz), 116.2 (d, J = 22.0 Hz), 76.0,
56.3, 41.9. IR (neat) 3336, 2926, 2373, 1696, 1556, 1402, 1218, 1099,
759, 694 cm−1; HRMS (ESI): C19H15ClFN3O3 [M + H]+ calcd,
388.0859; found, 388.0865.
</para>
<para sub=“exp”>
(2S,3S)-2-Chloro-4-nitro-1-(1-phenyl-1H-imidazol-2-yl)-3-(thio-
phen-2-yl)butan-1-one (5f). White solid, mp 115−117 °C; 28.6 mg,
76% yield (2.3:1); 96%/94% ee determined by HPLC on a Chiralpak
IA-H column (hexane/2-propanol = 60/40, ﬂow rate = 1.0 mL/min,
tminor = 8.2/8.7 min, tmajor = 7.4/11.8 min); [α]rt
D = 41.4 (c = 1.06,
CHCl3); 1H NMR (300 MHz, CDCl3) δ = 7.49−7.39 (m, 3H), 7.33
(dd, J = 4.1, 0.8 Hz, 1H), 7.29−7.18 (m, 2H), 7.17−7.07 (m, 2H), 6.93
(m, J = 13.9, 7.0, 3.3 Hz, 2H), 6.10 (d, J = 8.7 Hz, 1H), 5.13 (dd, J = 13.3,
4.1 Hz, 1H), 5.01 (m, J = 7.2, 3.6 Hz, 1H), 4.83 (dd, J = 13.3, 9.5 Hz,
1H), 4.63 (td, J = 9.1, 4.1 Hz, 1H) ppm; 13C NMR (75 MHz, CDCl3) δ =
181.6, 140.7, 137.3, 136.4, 130.8, 129.2, 128.6, 127.5, 126.1, 126.0, 125.4,
78.0, 57.9, 41.4 ppm; IR (neat) 3370, 2923, 2403, 1695, 1556, 1402,
1095, 1038, 760, 695 cm−1; HRMS (ESI): C17H14ClN3O3S [M + H]+
calcd, 376.0517; found, 376.0523.
</para>
<para sub=“exp”>

(2S,3S)-2-Chloro-3-(nitromethyl)-1-(1-phenyl-1H-imidazol-2-yl)-
nonan-1-one (5g). Colorless oil; 18.9 mg, 50% yield (6.4:1 dr); 75% ee
determined by HPLC on a Chiralpak IC-H column (hexane/2-propanol
= 60/40, ﬂow rate = 1.0 mL/min, tminor = 5.6 min, tmajor = 5.2 min); [α]rt
D
= 22.9 (c = 0.96, CHCl3); 1H NMR (300 MHz, CDCl3) δ = 7.49 (m, J =
6.6, 3.6 Hz, 3H), 7.35 (m, J = 1.7 Hz, 1H), 7.30 (m, J = 7.0, 2.6 Hz, 3H),
6.01 (d, J = 4.6 Hz, 1H), 4.72 (dd, J = 13.8, 4.5 Hz, 1H), 4.38 (dd, J =
13.8, 6.9 Hz, 1H), 3.11 (m, J = 10.6, 4.9 Hz, 1H), 1.68−1.46 (m, 4H),
1.35−1.26 (m, 6H), 0.89 (t, J = 6.6 Hz, 3H) ppm; 13C NMR (75 MHz,
CDCl3) δ = 183.1, 140.7, 137.6, 130.6, 129.2, 128.6, 125.7, 125.6, 75.6,
60.1, 39.9, 31.5, 30.5, 28.9, 26.2, 22.5, 14.1 ppm; IR (neat) 3372, 2928,
2370, 1696, 1554, 1401, 1306, 1037, 761, 694 cm−1; HRMS (ESI):
C19H24ClN3O3 [M + H]+ calcd, 378.1584; found, 378.1586.
</para>
<para sub=“exp”>
(3S)-Methyl 4-Nitro-3-phenyl-2-(p-tolyloxy)butanoate (6). 4a
(0.14 mmol, 61.9 mg, 1.0 equiv), 4 Å molecular sieves (70 mg), and
acetonitrile (1.4 mL) were combined in an oven-dried airtight ﬂask. The
suspension was stirred vigorously under a positive pressure of nitrogen
for 2 h. Methyl triﬂuoromethanesulfonate (56 μL) then was added. After
2 h another 14 μL of methyl triﬂuoromethanesulfonate was added, and
the reaction was stirred an additional 30 min. The reaction then was
cooled to 0 °C. MeOH (62.7 μL, 1.4 mmol, 10.0 equiv) and DBU (56.6
μL, 3.0 equiv) then were added stepwise. The reaction was stirred at 0
°C for 1 h before being quenched by 1 M HCl (10 mL) and extracted
with EA (3 × 15 mL), and the combined organic layer was dried over
anhydrous MgSO4 and the solvent was removed in vacuo. The product
was puriﬁed by ﬂash chromatography (PE:EA = 20:1) to give the
product 6, 13.2 mg, 30% yield (5.0:1 dr). White solid, mp 103−105 °C;
92% ee determined by HPLC on a Chiralpak IA-H column (hexane/2-
propanol = 80/20, ﬂow rate = 1.0 mL/min, tminor = 8.9 min, tmajor = 9.7
D = −67.8 (c = 0.58, CHCl3); 1H NMR (300 MHz, CDCl3) δ
min); [α]rt
= 7.33 (s, 5H), 7.06 (d, J = 8.3 Hz, 2H), 6.75 (d, J = 8.6 Hz, 2H), 5.05
(dd, J = 13.5, 5.5 Hz, 1H), 4.90 (dd, J = 13.5, 9.0 Hz, 1H), 4.78 (d, J = 6.0
Hz, 1H), 4.16 (m, J = 9.0, 5.7 Hz, 1H), 3.62 (s, 3H), 2.27 (s, 3H) ppm;
13C NMR (75 MHz, CDCl3) δ = 170.0, 154.9, 135.6, 132.0, 130.2, 129.1,
128.6, 128.2, 115.1, 78.9, 76.1, 52.5, 46.5, 20.5 ppm; IR (neat) 3342,
2961, 2372, 1752, 1556, 1381, 1261, 1090, 760, 701 cm−1; HRMS (ESI):
C18H19NO5 [M + Na]+ calcd, 352.1155; found, 352.1162.
</para>
<para sub=“exp”>
(3S)-Methyl 2-(Ethylthio)-4-nitro-3-phenylbutanoate (7). Syn-
thesis from 3p (0.1 mmol) and MeOH. White solid, mp 87−89 °C;
14.0 mg, 46% yield (4.1:1 dr); 95% ee determined by HPLC on a
Chiralpak IA-H column (hexane/2-propanol = 95/5, ﬂow rate = 1.0
D = −80.4 (c = 0.96,
mL/min, tminor = 12.8 min, tmajor = 13.7 min); [α]rt

CHCl3); 1H NMR (300 MHz, CDCl3) δ = 7.32 (m, J = 10.4, 2.9 Hz,
3H), 7.25−7.19 (m, 2H), 5.18 (dd, J = 12.9, 4.3 Hz, 1H), 4.75 (dd, J =
13.0, 9.8 Hz, 1H), 3.99−3.87 (m, 1H), 3.62 (d, J = 11.3 Hz, 1H), 3.52 (s,
3H), 2.73 (q, J = 7.4 Hz, 2H), 1.29 (t, J = 7.4 Hz, 3H) ppm; 13C NMR
(75 MHz, CDCl3) δ = 170.5, 136.7, 129.0, 128.4, 127.8, 78.3, 52.3, 49.4,
44.4, 25.6, 14.3 ppm; IR (neat) 3428, 2968, 2402, 1723, 1537, 1432,
1264, 1160, 763, 703 cm−1; HRMS (ESI): C13H17NO4S [M + Na]+
calcd, 306.0770; found, 306.0776.
</para>
<para sub=“exp”>
((1S,2R,3S)-2-Nitro-3-phenylcyclopropyl)(1-phenyl-1H-imidazol-
2-yl)methanone (8). 5a (0.50 mmol, 184.5 mg, 1.0 equiv), K2CO3 (0.50
mmol, 69.0 mg, 1.0 equiv), and DMF (2.0 mL) were combined in an
oven-dried airtight ﬂask. The reaction mixture was stirred at rt and
monitored by TLC before being quenched by NH4Cl (10 mL) and
extracted with EA (3 × 15 mL), and the combined organic layer was
dried over anhydrous Na2SO4 and the solvent was removed in vacuo.
The product was puriﬁed by ﬂash chromatography to give the product 8,
133.2 mg, 80% yield. Colorless oil. 96% ee determined by HPLC on a
Chiralpak OD-H column (hexane/2-propanol = 80/20, ﬂow rate = 1.0
mL/min, tminor = 13.4 min, tmajor = 14.2 min); [α]rt
D = 76.7 (c = 1.06,
CHCl3); 1H NMR (300 MHz, CDCl3) δ = 7.41−7.33 (m, 2H), 7.31 (d, J
= 7.9 Hz, 2H), 7.25 (m, J = 6.6, 3.5 Hz, 3H), 7.19 (m, J = 3.8 Hz, 3H),
6.89 (t, J = 5.4 Hz, 2H), 5.37−5.26 (m, 1H), 4.75 (dd, J = 11.7, 3.8 Hz,
1H), 3.94 (dd, J = 11.7, 4.9 Hz, 1H) ppm; 13C NMR (75 MHz, CDCl3) δ
= 180.6, 142.7, 137.4, 131.0, 130.5, 128.92, 128.91, 128.8, 128.5, 127.9,
127.7, 125.4, 62.8, 37.4, 36.9 ppm; IR (neat) 3343, 3026, 2964, 2363,
1680, 1548, 1415, 1046, 759, 693 cm−1; HRMS (ESI): C19H15N3O3 [M
+ H]+ calcd, 334.1186; found, 334.1194.
</para>
<para sub=“exp”>

(1S,2R,3S)-Methyl 2-Nitro-3-phenylcyclopropanecarboxylate (9).
Synthesis from 8 (0.26 mmol) and MeOH. Colorless oil; 47.5 mg, 83%
yield; 93% ee determined by HPLC on a Chiralpak IA-H column
(hexane/2-propanol = 80/20, ﬂow rate = 1.0 mL/min, tminor = 6.2 min,
D = −38.3 (c = 1.02, CHCl3); 1H NMR (300 MHz,
tmajor = 6.4 min); [α]rt
CDCl3) δ = 7.40−7.28 (m, 3H), 7.28−7.18 (m, 2H), 5.18 (dd, J = 4.8,
3.6 Hz, 1H), 3.66 (dd, J = 11.4, 4.9 Hz, 1H), 3.54 (s, 3H), 3.23 (dd, J =
11.4, 3.6 Hz, 1H) ppm; 13C NMR (75 MHz, CDCl3) δ = 166.3, 131.2,
128.7, 128.5, 128.3, 62.9, 52.5, 34.8, 32.1 ppm; IR (neat) 3341, 2957,
2373, 1738, 1552, 1371, 1206, 1063, 758, 697 cm−1; HRMS (ESI):
C11H11NO4 [M + Na]+ calcd, 244.0580; found, 244.0585.
</para>
■ ASSOCIATED CONTENT
*S Supporting Information
1H and 13C NMR spectra, copies of HPLC results, and
crystallographic data (CIF ﬁles). This material is available free
of charge via the Internet at http://pubs.acs.org.

■ AUTHOR INFORMATION
Corresponding Author
*E-mail: wangrui@lzu.edu.cn.
Notes
The authors declare no competing ﬁnancial interest.

■ ACKNOWLEDGMENTS

This work was supported by the NSFC (91213302, 91413107,
81473095, 21432003), the National S&T Major Project of China
(2012ZX09504001-003), and the Program for Changjiang
Scholars and Innovative Research Team in University (PCSIRT:
IRT1137), and the Innovation Group of Gansu Province
(1210RIIA002).

■ REFERENCES

(1) For pioneering works, see: (a) List, B.; Pojarliev, P.; Martin, H. J.
Org. Lett. 2001, 3, 2423. (b) Sakthivel, K.; Notz, W.; Bui, T.; Barbas, C.
F., III. J. Am. Chem. Soc. 2001, 123, 5260. (c) Enders, D.; Seki, A. Synlett
2002, 26. (d) Alexakis, A.; Andrey, O. Org. Lett. 2002, 4, 3611.
(2) For selected recent examples, see: (a) Avilaa, A.; Chinchillaa, R.;
Fiser, B.; Gómez-Bengoa, E.; Nájera, C. Tetrahedron: Asymmetry 2014,
25, 462. (b) Bächle, F.; Duschmal, J.; Ebner, C.; Pfaltz, A.; Wennemers,

4347

DOI: 10.1021/acs.joc.5b00013
J. Org. Chem. 2015, 80, 4336−4348

The Journal of Organic Chemistry
H. Angew. Chem., Int. Ed. 2013, 52, 12619. (c) Geertsema, E. M.; Miao,
Y.; Tepper, P. G.; Haan, P.; Zandvoort, E.; Poelarends, G. J. Chem.
Eur. J. 2013, 19, 14407. (d) Xu, K.; Zhang, S.; Hu, Y.; Zha, Z.; Wang, Z.
Chem.Eur. J. 2013, 19, 3573. (e) Sahoo, G.; Rahaman, H.; Madarsz,
Á.; Pápai, I.; Melarto, M.; Valkonen, A.; Pihko, P. M. Angew. Chem., Int.
Ed. 2012, 51, 13144. (f) Zheng, Z.; Perking, B. L.; Ni, B. J. Am. Chem. Soc.
2010, 132, 50. (g) Han, B.; Xiao, Y.; He, Z.; Chen, Y.-C. Org. Lett. 2009,
11, 4660. (h) Wu, J.; Ni, B.; Headley, A. D. Org. Lett. 2009, 11, 3354.
(i) Laars, M.; Ausmess, K.; Uudsemaa, M.; Tamm, T.; Kanger, T.; Lopp,
M. J. Org. Chem. 2009, 74, 3772. (j) Zhu, S.; Yu, S.; Ma, D. Angew. Chem.,
Int. Ed. 2008, 47, 545. (k) Lalonde, M. P.; Chen, Y.; Jacobsen, E. N.
Angew. Chem., Int. Ed. 2006, 45, 6366. (l) Mase, N.; Watanabe, K.; Yoda,
H.; Takabe, K.; Tanaka, F.; Barbas, C. F., III. J. Am. Chem. Soc. 2006, 128,
4966. (m) Hayashi, Y.; Gotoh, H.; Hayashi, T.; Shoji, M. Angew. Chem.,
Int. Ed. 2005, 44, 4212. (n) Wang, W.; Wang, J.; Li, H. Angew. Chem., Int.
Ed. 2005, 44, 1369.
(3) For selected examples, see: (a) Lu, A.; Liu, T.; Wu, R.; Wang, Y.;
Wu, G.; Zhou, Z.; Fang, J.; Tang, C. J. Org. Chem. 2011, 76, 3872.
(b) Ting, Y.-F.; Chang, C.; Reddy, R.; Magar, D.; Chen, K. Chem.Eur.
J. 2010, 16, 7030. (c) Jiang, X.; Zhang, Y.; Chan, A. S. C.; Wang, R. Org.
Lett. 2009, 11, 153. (d) Almas, D.; Alonso, D. A.; Nájera, C. Tetrahedron:
Asymmetry 2006, 17, 2064. (e) Pansare, S. V.; Pandya, K. J. Am. Chem.
Soc. 2006, 128, 9624. (f) Luo, S.; Mi, X.; Zhang, L.; Liu, S.; Xu, H.;
Cheng, J. Angew. Chem., Int. Ed. 2006, 45, 3093. (g) Cao, C.-L.; Ye, M.-
C.; Sun, X.-L.; Tang, Y. Org. Lett. 2006, 8, 2901. (h) Xu, Y.-M.; Córdova,
A. Chem. Commun. 2006, 460. (i) Cobb, A. J. A.; Longbottom, D. A.;
Shaw, D. M.; Ley, S. V. Chem. Commun. 2004, 1808. (j) Ishii, T.; Fujioka,
S.; Sekiguchi, Y.; Kotsuki, H. J. Am. Chem. Soc. 2004, 126, 9558.
(4) (a) Raimondi, W.; Baslé, O.; Constantieux, T.; Bonne, D.;
Rodriguez, J. Adv. Synth. Catal. 2012, 354, 563. (b) Baslé, O.; Raimondi,
W.; Sanchez Duque, M.; Bonne, D.; Constantieux, T.; Rodriguez, J. Org.
Lett. 2010, 12, 5246. (c) Xu, Y.; Matsunaga, S.; Shibasaki, M. Org. Lett.
2010, 12, 3246. (d) Nakamura, A.; Lectard, S.; Shiizu, R.; Hamashima,
Y.; Sodeoka, M. Tetrahedron: Asymmetry 2006, 17, 2064.
(5) For selected examples, see: (a) Kato, Y.; Furutachi, M.; Chen, Z.;
Mitsunuma, H.; Matsunaga, S.; Shibasaki, M. J. Am. Chem. Soc. 2009,
131, 9168. (b) Bui, T.; Syed, S.; Barbas, C. F., III. J. Am. Chem. Soc. 2009,
131, 8758. (c) He, R.; Shirakawa, S.; Maruoka, K. J. Am. Chem. Soc. 2009,
131, 16620. (d) Wang, C.; Yang, X.; Enders, D. Chem.Eur. J. 2012, 18,
4832. (e) Liu, X.; Song, H.; Chen, Q.; Li, W.; Yin, W.; Kai, M.; Wang, R.
Eur. J. Org. Chem. 2012, 6647. (f) Trost, B. M.; Hirano, K. Angew. Chem.,
Int. Ed. 2012, 51, 6480. (g) Qiao, B.; An, Y.; Liu, Q.; Yang, W.; Liu, H.;
Shen, J.; Yan, L.; Jiang, Z. Org. Lett. 2013, 15, 2358. (h) Diosdado, S.;
Etxabe, J.; Izquierdo, J.; Landa, A.; Mielgo, A.; Olaizola, I.; López, R.;
Palomo, C. Angew. Chem., Int. Ed. 2013, 52, 11846.
(6) (a) Albertshofer, K.; Thayumanavan, R.; Utsumi, N.; Tanaka, F.;
Barbas, C. F., III. Tetrahedron Lett. 2007, 48, 693. (b) Uehara, H.;
Barbas, C. F., III. Angew. Chem., Int. Ed. 2009, 48, 9848.
(7) (a) Andrey, O.; Alexakis, A.; Bernardinelli, G. Org. Lett. 2003, 5,
2559. (b) Trost, B. M.; Hisaindee, S. Org. Lett. 2006, 8, 6003. (c) Mossé,
S.; Alexakis, A. Org. Lett. 2006, 8, 3577. (d) Jiang, X.; Zhang, B.; Zhang,
Y.; Lin, L.; Yan, W.; Wang, R. Chirality 2010, 22, 625.
(8) For our recent interest in asymmetric reactions of linear ketones,
see: (a) Yang, D.; Wang, L.; Han, F.; Zhao, D.; Wang, R. Chem.Eur. J.
2014, 20, 8584. (b) Yang, D.; Wang, L.; Han, F.; Zhao, D.; Zhang, B.;
Wang, R. Angew. Chem., Int. Ed. 2013, 52, 6739.
(9) Yang, D.; Wang, L.; Li, D.; Han, F.; Zhao, D.; Wang, R. Chem.
Eur. J. 2015, 21, 1458.
(10) (a) Zhao, D.; Wang, L.; Yang, D.; Zhang, Y.; Wang, R. Angew.
Chem., Int. Ed. 2012, 51, 7523. (b) Yang, D.; Wang, L.; Han, F.; Li, D.;
Zhao, D.; Cao, Y.; Ma, Y.; Kong, W.; Sun, Q.; Wang, R. Chem.Eur. J.
2014, 20, 16478. (c) Wang, L.; Yang, D.; Han, F.; Li, D.; Zhao, D.;
Wang, R. Org. Lett. 2015, 17, 176. (d) Yang, D.; Wang, L.; Han, F.; Li,
D.; Zhao, D.; Wang, R. Angew. Chem., Int. Ed. 2015, 54, 2185.
(11) See the Supporting Information for the synthesis of ketones 1.
(12) For selected examples employing diaminocyclohexane-Ni(OAc)2
catalyst in asymmetric reactions, see: (a) Nakamura, A.; Lectard, S.;
Hashizume, D.; Hamashima, Y.; Sodeoka, M. J. Am. Chem. Soc. 2010,
132, 4036. (b) Deng, Q.-H.; Wadepohl, H.; Gade, L. H. Chem.Eur. J.

Article

2011, 17, 14922. (c) Li, W.; Liu, X.; Mao, Z.; Chen, Q.; Wang, R. Org.
Biomol. Chem. 2012, 10, 4767. (d) Zhang, H.; Hong, L.; Kang, H.; Wang,
R. J. Am. Chem. Soc. 2013, 135, 14098.
(13) CCDC 1041792 (3r) and CCDC 1041793 (5a) contain the
supplementary crystallographic data for this Article. These data can be
obtained free of charge from The Cambridge Crystallographic Data
Centre via www.ccdc.cam.ac.uk/data_request/cif. The Supporting
Information also contains the X-ray crystal structure details of products
3r and 5a.
(14) There is no reaction between these substrates:

(15) See the Supporting Information for the NOESY analysis.
(16) For our group’s recent interest in asymmetric synthesis of non-
natural amino acids precursors and modiﬁcation of the activities of
peptides with these amino acids, see: (a) Zhao, D.; Yang, D.; Wang, Y.;
Wang, L.; Mao, L.; Wang, R. Chem. Sci. 2011, 2, 1918. (b) Liu, X.; Wang,
Y.; Xing, Y.; Yu, J.; Ji, H.; Kai, M.; Wang, Z.; Wang, D.; Zhang, Y.; Zhao,
D.; Wang, R. J. Med. Chem. 2013, 56, 3102. (c) Wang, Y.; Xing, Y.; Liu,
X.; Ji, H.; Kai, M.; Chen, Z.; Yu, J.; Zhao, D.; Ren, H.; Wang, R. J. Med.
Chem. 2012, 55, 6224.

4348

DOI: 10.1021/acs.joc.5b00013
J. Org. Chem. 2015, 80, 4336−4348

